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Haematopoietic stem cell (HSC) contribution to liver repair varies considerably with
some of the observed variation and putative mechanisms (transdifferentiation and
fusion) possibly related to the type and severity of liver injury. More recently it has been
recognised that HSCs may also contribute to liver fibrosis. In both rodents and humans,
ethanol exposure induces hepatocyte death and inhibits the proliferative response of
adult hepatocytes resulting in the accumulation of hepatic stem cells within the liver
as part of a regenerative response to injury, although the precise origin of these cells
(hepatic vs. BM-derived) remains unclear. Studies on the extent of peripheral blood
HSC mobilisation in acute or chronic liver injury is however lacking and the degree of
contribution to liver repair from mobilised HSCs remains uncertain.
Aims:
1) To investigate the mobilisation and hepatic recruitment of HSCs in patients with
alcohol induced liver injury and define their contribution to parenchymal and non
parenchymal liver cell lineages.
2) To establish that mobilised HSCs in alcohol induced liver injury are functional and
demonstrate pluripotent stem cell properties.
3) To study the role of inflammatory cytokines and chemokine axes in regulating the
mobilisation and hepatic recruitment of HSCs in alcohol induced liver injury.
Methods:
Liver biopsies from alcoholic hepatitis (AH) patients andmale patients who had received
a female liver transplant (and who subsequently developed AH) were analysed for HSC
content using immunohistochemical and fluorescent in situ hybridisation techniques
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(FISH). FISH for Y-chromosome was performed on liver tissue, along with co-staining
for hepatocyte, biliary, myofibroblast and hepatic parenchymal cells proliferation
markers. Peripheral blood HSC (CD34+) levels were quantified in AH patients using
flow cytometry and CD347CD45+ HSC were collected and cultured in colony forming
unit (CFU) assays. CXCR3/CXCR4 receptor cell expression on mobilised CD34+
HSCs were quantified in AH patients using flow cytometry. Serum SDF-1, MMP-9,
G-CSF, IL-8, IP-10, MIG, RANTES, MCP-1 and neutrophil elastase (NE) levels in
AH patients were measured by enzyme linked immunosorbent assay (ELISA). Hepatic
expression of SDF-1, MMP-9 and NE were analysed using immunohistochemical
techniques in AH liver biopsies.
Results:
Patients with AH had increased numbers of CD34+ cells in liver tissue (1.83 ± 0.61%;
p<0.05) and in blood (0.2 ± 0.06%; p<0.05) as compared with appropriately matched
controls.Aproportion ofhepatic myofibroblasts were bonemarrow (BM) derived (7.9%
- 26.8%) as deemed by the co-localisation of the Y-chromosome and a-SMA staining.
In the cross sex liver grafts with AH, 5.03% of the myofibroblasts were co-staining
for CD34, suggesting that a population ofCD341 cells were contributing to the hepatic
myofibroblast population. In contrast, there was no evidence of BM contribution to
hepatocyte or biliary cell differentiation, nor evidence of increased hepatocyte cell
regeneration. Mobilised CD34+ cell CFU frequency in AH patients were significantly
higher as compared with NC HSCs (154 ± 38 vs. 44.75 ± 28.4, p<0.05). There was no
significant difference in either the percentage of CD34+ expressing CXCR4/CXCR3 or
receptor density / cell in the AH group when compared with the NC. Patients with AH
had significantly increased serum SDF-1 (1.4 ± 0.35ng/mL, p<0.05) levels and reduced
hepatic SDF-1 expression as compared with NC. Serum MMP-9 (260.05 ± 70.ling/
mL, p<0.05) levels were significantly increased whilst hepatic expression of MMP-9
was unchanged in AH patients as compared with NC. Serum G-CSF levels (29.73 ±
II
lO.lpg/mL, p<0.05) were significantly increased in AH patients as compared with
NC and there was a positive correlation between serum G-CSF levels and circulating
CD34+ cell levels in patients with AH. Serum IL-8, IP-10, MIG RANTES, MCP-1 and
NE levels demonstrated a non specific response to alcohol induced liver injury.
Conclusions:
Alcohol induced liver injury mobilises CD34+ HSCs into the peripheral circulation
and recruits them into the liver. These cells contribute to the hepatic myofibroblast
population but not to parenchymal lineages and their presence within the liver does
not promote hepatocyte repair. Mobilised HSCs from AH patients were functional and
displayed true stem cell potential at a level higher than control HSCs. Serum SDF-1,
MMP-9 and G-CSF rather than chemokine receptor expression, plays a central role in
regulating the mobilisation of CD34+ stem cells in alcohol induced liver injury.
12
Aims and Structure
This thesis aims to investigate themobilisation andhepatic recruitment ofhaematopoieti c
stem cells in patients with alcohol induced liver injury and define their contribution to
parenchymal and non parenchymal liver cell lineages. It aims to give insights into the
role inflammatory cytokines and chemokines regulate the process of haematopoietic
stem cell mobilisation and hepatic recruitment in alcohol induced liver injury.
The introduction of this thesis (Chapter 1) provides a general background on the
multilineage plasticity of haematopoietic stem cells and the mechanisms involved
in epithelial lineage regeneration. The contribution of haematopoietic stem cells to
liver repair is described in detail, as well as the contribution of bone marrow derived
stem cells to liver fibrosis. Current literature on the mobilisation of peripheral blood
haematopoietic stem cells and the regulatory role of inflammatory cytokines and
chemokine axes in liver injury is analysed. A discussion of the hepatic recruitment of
haematopoietic stem cells in liver injury togetherwith a description of the pathogenesis
of alcohol induced liver injury and the hepatic progenitor cell response in alcohol
induced liver injury is included. The application of bone marrow stem cell therapy in
liver disease and a synopsis of published clinical trials in this area is also discussed.
The concluding section provides explanation as to why alcohol related liver injury
was identified as a suitable injury model to study HSC mobilisation and recruitment
as well as to provide a discussion of the unanswered questions of HSC mobilisation
and contribution to liver repair in acute alcohol induced liver injury that will be
subsequently addressed in the thesis.
The first experimental chapter (Chapter 2) demonstrates the accumulation and
expansion of progenitor stem cells which express haematopoietic stem cell markers in
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alcohol induced liver injury and discusses whether hepatic progenitor cells are from
an endogenous hepatic or bone marrow derived source. The next chapter (Chapter
3) demonstrates the hepatic recruitment of bone marrow derived stem cells in alcohol
induced liver injury and explores the contribution ofbone marrow derived stem cells to
parenchymal and non parenchymal liver cell lineages. The promotion of endogenous
hepatocyte proliferation in a paracrine fashion by haematopoietic stem cells in alcohol
induced 1 iver injury is also investigated. Themobilisation ofendogenous haematopoietic
stem cells into the peripheral circulation ofpatients with alcohol induced liver injury is
described in the following chapter (Chapter 4). The stem cell potential and chemokine
receptor profiles of these mobilised haematopoietic stem cells are evaluated and their
contribution to regulating this mobilisation process in alcohol induced liver injury is
described.
The final analytical work (Chapter 5) describes the role of inflammatory cytokines
and chemokine axes in the mobilisation and recruitment of haematopoietic stem cells
in alcohol induced liver injury.
Finally there is a detailed critical discussion of the research highlighting the main
results and insights made by this thesis (Chapter 6).
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Chemokinc Nomenclature Appendix








The chemokines in this thesis have been referred to in the old nomenclature style as
this form of nomenclature was still widely used and referred to in publications at the
time of conducting the experiments for this thesis.
*As proposed by the International Union of Immunological Societies/World Health
Organisation Subcommittee on chemokine nomenclature (IUIS/WHO) 2001.
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1.1 Haematopoietic stem cell multi-lineage plasticity
The bone marrow (BM) compartment in humans comprises of committed progenitor
cells, mesenchymal stem cells (MSC) (which form stromal cells and cells of
mesodermal origin) and a larger stem cell population called haematopoietic stem
cells (HSCs) (Petersen et al. 1999). These HSCs have long been known to possess the
unique capacity for self-renewal and differentiation into cell lineages which sustain the
formation of the blood and immune systems throughout life. More recently it has been
observed that this plasticity extends to non-haematopoietic lineages such as, hepatic
progenitor cells, hepatocytes, cholangiocytes (Alison et al. 2000; Petersen et al. 1999;
Theise et al. 2000b), skeletal muscle cells (Ferrari et al. 1998), cardiac myocytes
(Orlic et al. 2001) neurons (Li et al. 2001), epithelial cells of the lung, GI tract and
skin (Korbling et al. 2002). This pathway of differentiation can be bi-directional with
reports demonstrating that both muscle and neuronal stem cells can also contribute to
haematopoiesis (Bjornson et al. 1999; Jackson, Mi & Goodell 1999).
Furthermore, emerging data in the field of cardiac regeneration suggests that incoming
stem cells can also contribute to tissue repair by promoting neoangiogenesis and
minimising cardiomyocyte apoptosis (Jackson et al. 2001). HSCs may also play a role
in stimulating endogenous hepatocyte proliferation in a paracrine fashion as evidenced
by their contribution in rodent (Yannaki et al. 2005) and human studies (Gaia et al.
2006) in which HSC are mobilised with granulocyte colony stimulating factor (G-
SCF).
This relatively new observation of HSC multilineage plasticity has raised hopes that
such cells could, in the future, be utilised for the regeneration and reconstitution
of damaged organ tissue. Embryonic stem cells (ESC) derived from the early post
implantation embryo are a source of pluripotent stem cells which can be utilised in
regenerative medical therapies however there are significant ethical and legal issues
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associated with its use, thus making HSCs an attractive alternative source of stem cells.
This process of epithelial lineage regeneration appears to occur via a process of either
spontaneous cell fusion and/or transdifferentiation (Masson et al. 2004) and whatever
the underlying mechanism by which the HSCs participate in tissue regeneration, it will
still require the presence of HSCs to mobilise from the BM and to reach their target
organ (Dalakas et al. 2005).
1.2 Adult stem cells and liver regeneration
Whilst the liver is a mitotically quiescent organ in adult humans and animals
(Alison, Poulsom & Forbes 2001), hepatocytes have a remarkable capacity to meet
the replacement demands during cellular loss (Alison 1998; Thorgeirsson 1996).
Hepatocytes are numerous and respond to liver injury such as partial hepatectomy and
centrilobular injury by one or two cell cycles although individual hepatocytes have
the capacity for up to 70 cell cycle divisions as demonstrated in serial transplantation
experiments (Overturf et al. 1997). However, when either chronic or extensive damage
is inflicted upon the liver or when hepatocyte proliferation is inhibited, a facultative
cellular compartment ofductular progenitor cells, located within the smallest branches
of the intrahepatic biliary tree is activated and leads to liver repair (Sell 2001;
Thorgeirsson 1996). In rodents these cells are named hepatic oval cells (HOC) whilst in
human they are referred to as hepatic progenitor cells (HPCs) (Roskams et al. 2004).
More recently, several groups have demonstrated thatBM derived HSCsmay contribute
to liver repair (Alison et al. 2000;Kollet et al. 2003;Lagasse et al. 2000;Petersen et al.
1999;Theise et al. 2000a;Theise et al. 2000b). The contribution ofHSCs to liver repair
has varied, but is generally related to the presence and severity of liver injury. These
haematogenously-derived stem cells have a very long proliferative potential and respond
to injury when neither HPCs nor mature hepatocytes are able to restore the injured
liver tissue (Sell 2001). Thus the restitutive response of the liver to different injuries
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has been proposed to include three levels of proliferating cells; 1) the hepatocyte, 2)
the endogenous ductular progenitor cell or HOC and 3) a pluripotent stem cell derived
from circulating BM cells (Alison 1998).
Controversy has recently arisen as to whether HSCs contribute to the hepatocyte
lineage in liver injury via transdifferentiation alone or by adopting the phenotype
of hepatocytes after spontaneous cell fusion (Austin & Lagasse 2003). Reports
in favour of the fusion hypothesis have demonstrated that stem cells can adopt the
phenotype of other cell lines by fusing with embryonal stem cells (Terada et al. 2002;
Ying et al. 2002). Terada et al demonstrated that murine bone marrow cells can fuse
spontaneously with embryonic stem cells when co-cultured in vitro with interleukin-3
and adopting the phenotype of the recipient embryonic stem cell. Furthermore, Wang
et al demonstrated that murine BM derived hepatocytes are generated by in vivo cell
fusion between donor BM cells and host hepatocytes in fumarylacetoacetate hydrolase
FAH-/- deficient mice (Wang et al. 2003c). In another murine injury model, Kashofer
et al transplanted human-enriched HSCs into carbon tetrachloride (CC14) induced liver
damaged non-obese diabetic/severe combined immunodeficient (NOD/SCID) mice
and identified donor derived hepatocytes. These hepatocytes occurred through cell
fusion and because no selective pressure was applied to retain the human genomic
material, it was lost over time, leading to a variable phenotype of the chimeric cells
(Kashofer, Siapati, & Bonnet 2006). In support of transdifferentiation, several groups
have demonstrated that HSCs can differentiate into hepatocytes (Ishikawa et al. 2003;
Newsome et al. 2003) and pancreatic endocrine cells (Ianus et al. 2003) without any
evidence of cell fusion. Recently Oh et al demonstrated that BM derived hepatic oval/
progenitor cells could differentiate into hepatocytes in a murine 2-acetylaminofluorene
(2-AAF) / partial hepatectomy (PH) liver injury model without any evidence that fusion
was contributing to the differentiation of donor-derived oval cells. The mechanism of
HSC hepatic regeneration remains unresolved and clearly any future stem cell research
will have to distinguish HSC transdifferentiation from fusion events (Oh et al. 2007).
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Whatever the mechanism of hepatic regeneration is, the trafficking of HSCs to the
liver will play an important component of the reparative process in liver injury.
The contribution ofHSCs to hepatocyte lineages in both rodents and humans remains
a controversial area with data both supporting (Alison et al. 2000; Lagasse et al. 2000;
Petersen et al. 1999; Theise et al. 2000a; Theise et al. 2000b; Wang et al. 2003b) and
rebutting findings (Dahlke et al. 2003; Kanazawa & Verma 2003; Wu et al. 2003). This
may, in part, reflect the types of cells used, the injury models used and the methods
used to detect stem cell progeny. Nevertheless a therapeutic role of HSCs in liver
injury has been described in rodents (Lagasse et al. 2000; Sakaida et al. 2004) albeit
with varying contributions of transdifferentiation and fusion. Legasse et al (Lagasse
et al. 2000) demonstrated the ability of BM derived cells to correct a metabolic liver
disease in female mice deficient in the enzyme fumarylacetoacetate hydrolase FAH-
/- an animal model of fatal hereditary tyrosinaemia type 1. The mice that received
intravenous injections of highly purified adult HSCs were rescued and biomedical
restoration of liver function was demonstrated.
In other models, and in particular in humans, the contribution that HSCs make to
liver repair by transdifferentiation is lower, in the order of 0.011-20% (Alison et al.
2000;Newsome et al. 2003;Theise et al. 2000b;Wu et al. 2003). Both Theise et al
(Theise et al. 2000b) and Alison et al (Alison et al. 2000) have demonstrated that BM
cells can contribute to liver regeneration in damaged human liver tissue, although the
degree of hepatic engraftment was highly variable. In both studies liver specimens
from human recipients of therapeutic BM or liver transplants, inwhich there was gender
discordance between donor and recipient, were analysed by in situ hybridisation for
the Y-chromosome. Alison et al reported that the frequency ofY positive hepatocytes
ranged from 0.5 to 2%, a value that correlates with previous murine studies whilst
Theise et al reported a more variable hepatocyte engraftment range. The variability
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in engraftment rate between the two studies can partly be due to Theise et al using
a five fold correcting factor to account for the frequency of Y-chromosome positive
hepatocytes in the normal male liver. Theise et al also noted that the extent of
hepatocyte engraftment correlated with the extent of liver injury (Theise et al. 2000b).
With mild liver injury, hepatocyte engraftment occurred at lower levels ranging from
5% to 19% and in one case of severe injury (recurrent hepatitis C), the engraftment rate
increased to 40%. Further studies have however reported significantly lower levels of
HSC contributions to liver repair. To improve on this level of contribution will require
a greater understanding of the mechanisms by which stem cells mobilise from the
BM and home to injured organs. There remains a pressing need however, for further
studies to confirm or refute the claims that stem cells can lead to improved liver repair
and hence survival in either rodent or human setting.
1.3 Bone marrow stem cells and liver fibrosis
Chronic hepatic injury is usually accompanied by progressive fibrosis and the
inflammatory response to the hepatic injury activates hepatic stellate cells (HpSC)
which proliferate and synthesise collagen (Kallis, Alison, & Forbes 2007). These
HpSC display alpha-smooth muscle actin (a-SMA), a myofibroblasts marker and are
thought to be central in the pathogenesis of liver fibrosis (Lau et al. 2005; Nouchi
et al. 1991; Russo et al. 2005). Recently it has been recognised that BM derived
stem cells contribute more significantly to non parenchymal cell lineages such
as hepatic endothelium (Gao, McAlister, & Williams 2001), stellate cells (Baba et
al. 2004) and myofibroblasts (Russo et al. 2006). Russo et al demonstrated that in
chronic chemical injury up to 70% of the murine hepatic myofibroblast population
were derived from the mesenchymal stem cell (MSC) component of the BM (Russo et
al. 2006). Furthermore, studies examining BM transplantation from the Colla mouse
(which produces a mutated collagenase resistant form of collagen) into wild-type
mice demonstrated that the phenotype of liver fibrosis would appear, in part, to be
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dependent on the BM (Russo et al. 2006). Recently, another cell type was implicated
with the generation of liver fibrosis. Kisseleva et al demonstrated that BM-derived
fibrocytes contributed up to 5 to 10% of all collagen expressing cells in the bile duct
ligated model of injury (Kisseleva et al. 2006). Fibrocytes are circulating cells derived
from haematopoietic stem cells (Ebihara et al. 2006) that express markers for both
haematopoietic cells and fibroblasts, producing collagen and other matrix proteins,
but which generally do not express a-SMA (myofibroblast marker) in vivo (Abe et al.
2001). In addition to their contribution to hepatic scarring they have been shown to
make a significant contribution to pulmonary (Phillips et al. 2004), renal (Sakai et al.
2006) and cutaneous (Mori et al. 2005) scarring. Analysis ofarchival human tissue has
identified that 6-22% of hepatic myofibroblasts are BM derived (Forbes et al. 2004).
1.4 HSC mobilisation in liver injury
Fluman studies have demonstrated increased levels of circulating HSCs in response to
a systemic injury such as acute sickle cell crisis, ischaemic stroke, acute myocardial
infarction and surgical trauma (Grzelak et al. 1998; Lamming et al. 2003; Paczkowska
et al. 2005). In the context of human liver injury, elevated levels of peripheral blood
HSCs have been demonstrated following extensive liver resection in patients with
malignant, primary or secondary liver diseases (De Silvestro et al. 2004). Furthermore,
following partial hepatectomy in living liver donors there appears to be a mobilisation
of BM derived progenitor cells with in-vitro hepatic differentiationpotential (Gehling
et al. 2005). Kyriakou et al demonstrated elevated levels of circulating peripheral
blood HSCs in patients with autoimmune hepatitis but not in patients with primary
biliary cirrhosis or cirrhotics of viral or alcohol aetiology (Kyriakou et al. 2003). A
recent study by Lemoli et al demonstrated HSCs mobilisation to be more pronounced in
liver transplant patients with ischaemic/reperfusion injuries as compared with patients
undergoing liver resections and suggesting that the greater the extent of liver tissue
injury the higher the degree of HSC mobilisation (Lemoli et al. 2006). Studies on the
30
extent ofperipheral blood HSC mobilisation in acute or chronic alcohol liver injury is
however lacking and the degree of contribution to liver repair from mobilised HSCs
remains uncertain.
1.4.1 SDF-1 and HSC mobilisation from the bone marrow
In the adult BM, the release of HSCs into the peripheral circulation is regulated in
part by the CXC chemokine stromal cell-derived factor-1 (SDF-1) and its receptor
CXCR4 (Aiuti et al. 1997; Kim & Broxmeyer 1998a; Lapidot & Petit 2002; Petit et al.
2002). SDF-1 is a potent chemoattractant for HSCs and is produced by various BM
stromal cell types and epithelial cells in a broad range of normal tissues including the
liver (Bajetto et al. 1999; Casamayor-Palleja et al. 2001; Godiska et al. 1995; Jiang et
al. 1994; Pablos et al. 1999; Tashiro et al. 1993; Zaitseva et al. 2002) (see table 1). It
plays a major role in the homing, migration, proliferation, differentiation and survival
ofmany cell types including human and murine haematopoietic stem/progenitor cells
(Aiuti et al. 1997; Bleul, Schultze, & Springer 1998; D'Apuzzo et al. 1997; Lapidot &
Petit 2002; Mohle et al. 2001; Petit et al. 2002; Whetton & Graham 1999). Knockout
mice deficient in SDF-1 exhibit disturbed haematopoiesis, and knockout mice deficient
in the CXCR4 receptor die in utero (Kawabata et al. 1999; Nagasawa et al. 1996),
underlining their importance.
SDF-1 is highly conserved between mice and humans (Kollet et al. 2002; Sweeney
& Papayannopoulou 2001), mediating its effect through the CXCR4 receptor that is
expressed on CD34+ HSCs, mononuclear leucocytes as well as a variety of stromal
cells (Kollet et al. 2002). CXCR4 is a G-protein-coupled, 7-transmembrane receptor
and is the only known receptor for SDF-1 (Nagasawa, Tachibana, & Kawabata 1999).
The interaction between SDF-1 and CXCR4 has been demonstrated to triggermultiple
intracellular signals including calcium mobilisation and phosphorylation of adhesion
components such as extracellular-signal regulated kinases 1 and 2 (ERK-1 and -2),
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proline-rich tyrosine kinase 2 (Pyk-2), focal adhesion kinase (FAK) and protein kinase
C (PKC) (Roland et al. 2003;Wang, Park, & Groopman 2000). In the adult BM, the
release of HSC into the peripheral circulation is controlled in part by a concentration
gradient of SDF-1 established within the BM microenvironment (Bleul et al. 1996;Kim
et al. 1998b;Kim & Broxmeyer 1998a). Reduction of BM SDF-1 levels has been
shown to result in release of HSC into the peripheral circulation, an effect partly
mediated by granulocyte colony-stimulating factor (G-CSF) which induces the release
and synthesis ofneutrophil proteases such as neutrophil elastase (NE), cathepsin G and
matrix metalloproteinases (MMP) (Petit et al. 2002). In addition, increased expression
of SDF-1 in the peripheral circulation facilitates further mobilisation of HSCs down a
concentration gradient (Hattori et al. 2001).
In the context of human liver injury there are several reports demonstrating increased
circulating plasma levels of SDF-1 in autoimmune and viral diseases, in conjunction
with increased expression of SDF-1 in the parenchyma of rejecting liver transplants
and viraPautoimmune liver diseases (Goddard et al. 2001;Terada et al. 2003). These
observations have also been reported in murine liver injury models (Hatch et al.
2002;Kollet et al. 2003), suggesting that liver injury may by the expression of SDF-1,
produce a concentration gradient between liver and BM, which in turn facilitates the
recruitment of inflammatory cells and HSCs from the BM into the circulation and then
into the liver (Dalakas et al. 2005;Kollet et al. 2003;Terada et al. 2003) (see figure
la-lc).
The mechanism by which SDF-1 influences HSC mobilisation is unclear, although
it is thought to involve specific changes to the adhesion of progenitor cells to the
BM microenvironment via the modulation of adhesion molecules such as the integrin-
dependant very late antigen-4 (VLA-4) (Peled et al. 2000). In vitro there is an increased
trans-endothelial migration of human progenitor cells towards a gradient of SDF-1
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(Mohle et al. 2001;Netelenbos et al. 2002) and furthermore SDF-1 has been shown to
promote the survival of circulating CD34+ HSCs by counteracting apoptosis via the
activation of the phosphotidyl inositol 3 kinase (PI3-K)/Akt pathway (Lataillade et al.
2002).
It has been speculated that the release of proteolytic enzymes and chemokines from
injured liver into the circulation could also facilitate mobilisation and recruitment of
HSCs (Kollet et al. 2003). Studies with G-CSF have revealed neutrophil proteolytic
enzymes such as neutrophil elastase (NE), cathepsin G and MMP's, including MMP-
2 and MMP-9, resulting in the proteolytic degradation of SDF-1 in the BM, thus
facilitating the release of stem cells (Levesque et al. 2003;Petit et al. 2002). NE
and cathepsin-G are capable of proteolytic cleavage of key molecules vascular cell
adhesion molecule-1 (VCAM-1) (Levesque et al. 2001) and SDF-1 (Petit et al. 2002),
which regulate HSC trafficking in the BM. NE and CG deficient mice however display
normal G-CSF induced HSC mobilisation (Levesque et al. 2004) and consequently the
role ofNE and cathepsin-G in HSC mobilisation remains uncertain.
1.4.2 MMP-9 and HSC mobilisation from the bone marrow
MMPs degrade extracellular matrix proteins and are known to play important roles
in tissue inflammation, tumour growth and organ remodelling (Birkedal-Hansen
et al. 1993;Visse & Nagase 2003). MMPs are secreted as zymogens (pro-MMPs)
which are activated by a variety of proteinases and are inhibited by tissue inhibitors
ofmetalloproteinases (TIMPs) and a2-macroglobulin (Birkedal-Hansen et al. 1993).
In humans, MMP-9 is produced in a wide variety of cells types such as neutrophils,
progenitor cells, endothelial cells, fibroblasts, connective tissue cells, tumour cells
and parenchymal cells, including the liver (Birkedal-Hansen et al. 1993;Geisler et
al. 1997). Human and animal studies have demonstrated that MMP-9 promotes the
release of progenitor cells from the BM into the circulation by; 1) inducing the release
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of soluble Kit-ligand (sKitL) from BM stromal cells which accelerates the proliferation
and migration of HSCs, 2) cleaving the interaction of adhesion molecules VLA-4/
VCAM-1 between stromal cells and HSCs in the BM and 3) enhancing the SDF-1
induced migration potential of HSCs across the subendothelial basement membrane
(Aiuti et al. 1997;Hattori et al. 2002;Heissig et al. 2002;Janowska-Wieczorek et al.
2000). In addition, MMP-9 induced recruitment of HSCs may also occur via other
mechanisms such as the shedding of membrane bound stem cell factor (SCF) and the
secretion ofMMP-9 by progenitor cells in response to SDF-1 stimulation (Heissig et
al. 2002;Janowska-Wieczorek et al. 2000). MMP-9 has been demonstrated to have
an active involvement in liver remodelling in cirrhosis and inflammation as well
as regulating hepatocyte regeneration after partial hepatectomy (Haruyama et al.
2000;Kuyvenhoven et al. 2004b;Lichtinghagen et al. 2003).
Human studies have demonstrated elevated serum and plasma MMP-9 levels in
various types of liver injury including acute allograft rejection (Kuyvenhoven et al.
2004b), ischaemic reperfusion injury (Kuyvenhoven et al. 2003;Kuyvenhoven et al.
2004a), chronic viral hepatitis (Chung et al. 2004;Leroy et al. 2004) and alcoholic liver
cirrhosis (Kwon et al. 2003), suggesting that there is a correlation between disease
severity/progression and MMP-9 expression. In these studies 70-80% of the serum
and plasma MMP-9 measured, appeared in the active complex form and could be
detected in serum samples from as early as 30 minutes and greater than 1 week after an
acute injury process. In chronic liver diseases such as alcoholic cirrhosis persistently
elevated plasma activities of MMP-9 have been demonstrated suggesting that its
expression reflects a process of ongoing extracellular matrix remodelling (Kwon et al.
2003).
Carbon tetrachloride (CC14) induced liver injury studies in rat and NOD/SCID mice (in
which bone marrow cells were seen to transdifferentiate into hepatocytes) demonstrated
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an increased expression and activation of MMP-9 in the liver, suggesting that this
factor could potentially be involved in the stress-induced recruitment of HSC from
the BM to the injured liver (KLnittel et al. 2000;Kollet et al. 2003). A recent study by
Hanumegowda et al (Hanumegowda et al. 2003), has also demonstrated an increased
activation ofMMP-9 in the livers of rats with monocrotaline induced liver injury (which
inhibits hepatocyte proliferation and promotes an HOC response). This increase in
MMP-9 activity was produced from either the endothelial cells or from an activation
or influx of inflammatory cells into the injured hepatic parenchyma (Hanumegowda et
al. 2003). Furthermore in a study by Watanabe et al, mice were injected with anti-Fas
antibody (Jo2) to induce an acute hepatitis, demonstrating that MMP-9 expression in
the circulation was elevated and accompanied by the recruitment of HSCs from the
BM into the circulation (Watanabe, Haruyama, & Akaike 2003) (seefigure lb).
1.4.3 G-CSF and HSC mobilisation from the bone marrow
Immune and inflammatory stimuli promote the production of the cytokine G-CSF which
induces the mobilisation and proliferation ofHSCs and haematopoietic progenitor cells
(HPCs). G-CSF is a potent cytokine which is utilised extensively for the mobilisation
of HPC in both clinical and research applications (Mohle & Kanz 2007) and induces
a highly proteolytic microenvironment in the BM during the mobilisation process
(Levesque et al. 2002). Disruption of the SDF-1/CXCR4 signalling pathway is a key
step in G-CSF mediated HSC mobilisation resulting in a decrease in bone marrow SDF-
1 levels (Levesque et al. 2003;Petit et al. 2002;Semerad et al. 2002) and inactivation of
the CXCR4 receptors on HSCs (Levesque et al. 2003).
Human studies have demonstrated that mobilised CD34+ cell levels in the peripheral
circulation of patients with acute myocardial infarction significantly correlates
with elevated levels of endogenous G-CSF (Leone et al. 2006) and that G-CSF
administration results in improved myocardial perfusion after subacute ST-segment
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elevation myocardial infarction undergoing late revascularisation (Engelmann et al.
2006). Murine chemical liver injury (CC14, thioacetamide (TAA) & 2-AAF) and
hepatectomy studies have demonstrated that G-CSF administration improves survival
rate and liver regeneration by; 1) promoting endogenous repair and proliferation ofhost
hepatocytes, 2) mobilising HSCs into the injured liver to differentiate into hepatocytes
by enhancing the endogenous hepatic oval cell reaction and 3) promoting in vivo
cell fusion of HSCs with hepatocytes (Fiu et al. 2006;Piscaglia et al. 2007;Quintana-
Bustamante et al. 2006;Theocharis, Margeli, & Kittas 1999;Yannaki et al. 2005). In the
context of human liver injury, serum G-CSF concentrations are elevated after hepatic
resection and ischaemic reperfusion injuries with preservation of hepatic parenchymal
cell function (Hanazaki et al. 2001). Femoli et al has demonstrated that tissue damage
after orthotopic liver transplantation (OFT) and liver resection induces increased serum
G-CSF levels but only the ischaemic reperfusion injury associated with OFT results in
the mobilisation of BM stem/progenitor cells (Femoli et al. 2006).
1.4.4 Chemokines IL-8, MIG, IP-10, RANTES and MCP-1 in HSC
mobilisation
The interactions between MMP-9 and other chemokines such as Interleukin-8 (IF-8)
has also been demonstrated in mobilisation studies whereby MMP-9 is rapidly induced
in neutrophils following exposure to (IF-8) and resulting in the release of HSCs into
the peripheral circulation (Carion et al. 2003;Fibbe et al. 1999;Pruijt et al. 2002;Van
Zee et al. 1992) (see figure lb). Elevated IF-8 levels have been demonstrated in the
circulation and hepatic parenchyma ofmany human liver conditions including alcoholic
hepatitis, viral hepatitis, chronic alcoholic liver disease and acute graft-versus-host
disease following liver transplantation (Hill, Marsano, & McClain 1993;Huang et al.
1996;Sheron et al. 1993;Shimoda et al. 1998;Tilg et al. 1992). Thus IF-8 which is a
known neutrophil chemoattractant in liver disease, also has the potential to induce the
release of HSCs into the peripheral circulation via an indirect mechanism requiring
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the activation of circulating neutrophils and the release ofMMP-9 (Pruijt et al. 2002).
The chemokines Monokine-induced by Interferon-y (MIG) and Interferon-y-induced
Protein-10 (IP-10) which mediate their effect through chemokine receptor CXCR3,
are thought to be important in recruiting T lymphocytes into the injured liver as well
as playing a crucial role in CD34+ HSC adhesion (Jinquan et al. 2000;Nanji et al.
1999). IP-10 and MIG can induce phosphorylation of CD34+ progenitors which leads
to CXCR3 expression and induces chemotaxis and adhesion ofCD34+ haematopoietic
progenitor cells (Jinquan et al. 2001). This would suggest that CXCR3, IP-10 and
MIG may be important in the cytokine/chemokine environment for the mobilisation,
homing and recruitment of haematopoietic progenitor cells (Jinquan et al. 2001). IP-
10 has both an in vitro and in vivo ability to enhance neural progenitor cell migration
(Honeth et al. 2006) and also has a hepatoregenerative effect in a mouse model of
acute paracetamol liver injury (Bone-Larson et al. 2001). The chemotactic cytokine
RANTES and Monocyte Chemoattractant Protein-1 (MCP-1) have been shown to
be up-regulated in CD34+ stem cells when stimulated by inflammatory cytokines
(including TNF-alpha) and which may contribute to an active role for CD34+ HSCs
during inflammation and immunological events (Umland et al. 2004). Gene expression
of MCP-1 is up-regulated in human CD34+ progenitor cells when implanted in a
hypoxic environment and has been shown to generate rapid tissue neovascularisation,
possibly via recruitment ofmonocytes and/or macrophages (van der Strate et al. 2007).
These chemotactic and inflammatory cytokines could therefore also be important in
the recruitment and differentiation of HSCs in liver disease.
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1.5 Hepatic recruitment of HSCs in liver injury (seefigure lc)
Kollet et al have recently demonstrated the key role that SDF-1/CXCR4 mediated
signallingplays in the migration ofhuman progenitors to the murine liver. Neutralisation
of the CXCR4 receptor with an anti-CXCR4 antibody significantly inhibited the
homing ofhuman cord blood or mobilised peripheral blood CD34+ stem cells to the
liver of irradiated NOD/SCID mice. Furthermore, injection ofhuman SDF-1 into the
murine liver parenchyma further enhanced the hepatic migration ofhuman stem cells.
SDF-1 expression has been reported in a variety of liver and non-liver conditions such
as liver allograft rejection (Goddard et al. 2001), viral and autoimmune liver diseases
(Terada et al. 2003), ischaemic brain injury (Stumm et al. 2002), myocardial infarction
(Pillarisetti & Gupta 2001), inflammatory skin conditions (Pablos et al. 1999) and BM
injury induced by total body irradiation or chemotherapy (Ponomaryov et al. 2000).
It is unclear if this expression is an attempt to recruit inflammatory cells or HSCs
towards the damaged organ, or if it is indeed entirely unrelated.
SDF-1 expression in rejecting liver transplants and viral/autoimmune liver diseases
was seen to be confined to the biliary epithelium and other non-parenchymal cells,
thus promoting the retention of CXCR4+ lymphocytes and possibly HSCs in the portal
tracts (Goddard et al. 2001;Terada et al. 2003). Hatch et al (Hatch, Zheng, Jorgensen,
& Petersen 2002) were able to demonstrate that SDF-1 protein was up-regulated in the
membrane fraction of the whole liver lysates. Notably however, this was only the case
in animals that had undergone HOC regeneration models [partial hepatectomy (PH)
and 2-acetylaminofluorene (2AAF) or 2AAF and CC14], Animals that had undergone
non-oval cell regeneration models ofPH, CC14 alone and 2-AAF alone did not produce
SDF-1 protein. Immunohistochemistry on the oval cell regeneration model liver
sections revealed increased expression of SDF-1 in the hepatocytes adjacent to the
proliferating oval cells and positive CXCR4 staining on these oval cells. This data
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argues for the defined production of SDF-1 in forms of liver injury which may be
attempting to recruit HSCs to the reparative process.
The cytokine hepatocyte growth factor (HGF) which is produced in the non parenchymal
peri-sinusoidal cells of the liver and induces hepatocyte proliferation may in addition
to SDF-1 also be involved in the migration and differentiation of HSC into the injured
liver (Kiss et al. 2001;Kollet et al. 2003). Increased expression of HGF has been
demonstrated in CC14 induced liver injury and in rodent HOC regeneration models
suggesting that it is involved in stem cell proliferation, migration and differentiation
(Alison et al. 1993;Wang et al. 2003b). Kollet et al have demonstrated that following
liver injury levels ofHGF were increased and contributed to the recruitment of human
CD34+ stem cells to the injured liver by increasing the motility of human progenitors
and in synergy with stem cell factor (SCF) potentiated both CXCR4 and SDF-1 induced
directional migration (Kollet et al. 2003).
1.6 Pathogenesis of alcohol induced liver injury
1.6.1 Alcohol induced oxidative stress
Current evidence suggests that alcoholic liver damage involves all hepatic cellular
components (hepatocytes, Kupffer, stellate and endothelial cells) at some stage of its
pathogenesis and is the end result of a complex interplay between ethanol metabolism,
inflammation and immunity (Sougioultzis et al. 2005). Ethanol is oxidized in
hepatocytes first to acetaldehyde and subsequently to acetate, via two well-studied
metabolic pathways. The first is the combination of cytosolic alcohol dehydrogenase
and mitochondrial aldehyde dehydrogenase leading to its sequential oxidation; the
second is the ethanol-inducible microsomal ethanol oxidizing system (MEOS) with
its major component, cytochrome P450 2E1 (CYP2E1) (Tsukumato & Lu 2001).
Ethanol oxidation in the liver parenchyma generates reactive free radicals such as
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reactive oxygen (ROS) and nitrogen intermediates (RNS) leading to oxidative stress, a
condition that is further reinforced by the depletion of the antioxidants glutathione and
vitamin E observed in chronic alcoholics (Bjorneboe et al. 1988;Tsukamoto & Lu 2001).
Oxidative stress in alcoholic liver disease is therefore mediated by both an increase in
pro-oxidant overproduction and a decrease in antioxidant defences. Oxidative stress
primes the transcription of several cytokines and growth factors, potentially from all
hepatic cell types, leading to the attraction of immune cells to the hepatic parenchyma
and resulting in the peroxidation of membrane and lipoprotein lipids which facilitate
cellular necrosis, apoptosis and activation of fibrogenesis (Natori et al. 2001;Stewart,
Jones, & Day 2001;Ziol et al. 2001).
Acetaldehyde and other reactive molecules generated through ethanol oxidation have
the propensity to bind covalently to proteins to form adducts which are potential neo-
antigens that trigger host's adaptive immune response. Anti-acetaldehyde antibodies
have been found in alcoholics (Koskinas et al. 1992;Niemela et al. 1987) and correlated
with the severity of liver injury (Viitala et al. 1997) suggesting that they are probably
involved in alcohol induced hepatic damage. Oxidative stress may also facilitate
the production of auto-antibodies against phospholipids, alcohol dehydrogenase,
cytochrome P4502E1 and antinuclear antibodies, which are detectable in 25-50%
of patients with AH and cirrhosis (Chedid et al. 1994;Laskin et al. 1990;Ma et al.
1997;Vidali et al. 2003). However, the role of autoimmunity in the pathogenesis of
liver damage in alcoholics still remains speculative (Albano 2002).
Apart from the direct and indirect insults of ethanol to the liver, recent evidence
suggests that alcohol ingestion also increases the translocation of endotoxin, and
possibly other noxious substances, from the gut lumen to the portal circulation (Bode,
Kugler & Bode 1987;Keshavarzian et al. 1999). Endotoxin in turn, stimulates Kupffer
cells to produce cytokines and free radicals, therefore perpetuating the oxidative stress,
increasing further the hepatic cytokine load. Taken together, all the above constitute
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the current working hypothesis towards a rational and mechanistic approach to alcohol
mediated liver injury. It should be pointed out that the exact sequence of events that
leads to severe liver damage in alcoholics is still incompletely understood.
1.6.2 Cytokines and inflammatory mediators in alcohol liver injury
A lot of attention has been focused recently on the role of tumour necrosis factor alpha
(TNF-a) and apoptosis in the pathogenesis of alcohol induced liver injury. TNF-a
is a macrophage-derived factor and is considered a key mediator in a wide variety
of biological processes such as fever, septic shock, tissue injury, tumor necrosis and
apoptosis. TNF-a transcripts trimerize to form the 51kD active TNF-a ligand which
can bind to either a 55kD receptor (TNFR1), present on most cell types, or to a 75kD
receptor (TNFR2), expressed mainly by immune and endothelial cells (Aggarwal
2003). The wide distribution of TNF receptors provides a possible explanation for
its diverse biological effects. After binding to its receptors, TNF-a triggers a complex
intracellular signalling cascade involving the activation of the transcription factor
NF-kB and mitogen-activated protein kinases (MAPKs), resulting in the production
of proinflammatory cytokines, such as interleukin 6 (IL-6) and interleukin 8 (IL-8)
and upregulation of adhesion molecules (Aggarwal 2003). TNF-a can also induce
apoptosis in a wide variety of cell types (Gaur & Aggarwal 2003). However, normal
hepatocytes seem to be resistant to the pro-apoptotic action ofTNF-a, an effect that is
thought to be mediated by the anti-apoptotic properties ofNF-kB (Tilg & Diehl 2000).
In addition, animal studies have shown that TNF-a initiates liver regeneration after
partial hepatectomy by activating TNFR1 (Yamada et al. 1997). Despite the above
observations that suggest a rather beneficial effect in the normal liver, TNF-a has been
reported elevated in admission sera ofpatientswithAH and its levels have been correlated
with disease severity and mortality (Bird et al. 1990;Felver et al. 1990). Concurring
animal studies have shown that TNFR1 knockout mice are resistant to alcohol induced
liver damage (Yin et al. 1999) and that the administration ofTNF-a antibodies prevents
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liver injury in alcohol-fed rats (limuro et al. 1997). It is therefore believed that TNF-
a biologic activities are altered in alcoholic liver disease, favouring inflammation and
apoptosis rather than hepatocyte proliferation. The underlying molecular mechanisms
are still unclear but ongoing research suggests that alterations in the NF-kB related
signalling (Heyninck, Wullaert, & Beyaert 2003) probably influenced by the cytokine
milieu and other pro-apoptotic pathways are involved (Stewart, Jones, & Day 2001 ;Tilg
& Diehl 2000). The expressionof the pro-inflammatory cytokine transforming growth
factor-beta (TGF-(3) is increased in alcoholic liver injury (Fang et al. 1998;Neuman
et al. 2002) and has been shown to enhance hepatic fibrogenesis. TGF-(3 stimulates
the activation of hepatic stellate cells which in turn promotes extra cellular matrix
and collagen production within the hepatic parenchyma and leads the development
of liver fibrosis. In addition, TGF-[3 has been shown to suppress the proliferation of
hepatocytes as well as mediating hepatocyte apoptosis in alcohol induced liver injury
(Gressner et al. 2002;Neuman 2003). Other chemokines such as IL-8, macrophage
inflammatory protein 2 (MIP-2) (murine equivalent of human IL-8), cytokine induced
neutrophil chemoattractant (CINC) (rodent equivalent of human IL-8) and MCP-1 and
have all been shown to be elevated in alcohol induced liver injury (Fang et al. 1998;
Sheron et al. 1993). Many different cells, including Kupffer cells and hepatocytes,
produce these chemokines and it is thought that they participate in the recruitment of
neutrophils to the site of alcohol liver injury by promoting neutrophil migration from
the hepatic sinusoids through the endothelial lining and into the hepatic parenchyma
(Purohit & Russo 2002). A potential mechanism by which this neutrophilic infiltration
damages hepatic parenchymal cells is via neutrophil derived oxidant stress and protease
enhanced cell injury. Adhesion molecules are also important factors in the migration
of neutrophils and the primary adhesion molecules that participate in this process are
selectin, (32 integrins, and intercellular adhesion molecule (ICAM)-l. The (32 integrins
are expressed on neutrophils, whereas ICAM-1 is expressed on endothelial cells and
hepatocytes (Purohit & Russo 2002).
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The chemokine IP-10 is a potent chemoattractant foralloantigen-primedT cells (Farber
1997) and several studies have reported increased hepatic expression of this chemokine
in animal models ofalcoholic liver injury (Nanji et al. 1999). IP-10 is thought to play an
important role in the activation of integrins on the cell surface of recruited lymphocytes,
however the effects of IP-10 in alcohol induced liver injury remain obscure (Purohit
& Russo 2002). Previous studies have demonstrated that acute alcohol consumption
induces IL-10 production, a potent, immunoregulatory cytokine in human monocytes
(Mandrekar et al. 2006;Szabo et al. 1996). One possible mechanisms by which ethanol
use disturbs cellular immune responses maybe a result of elevated IL-10 production
by macrophages and T lymphocytes which promote humoral immune responses and
inhibit cellular immune responses by down-regulating the production ofThl cytokines,
antigen-specific T cell proliferation, and proinflammatory cytokine levels including
TNF-a (de Waal, Y et al,1993;Szabo et al. 2004). Although the immunomodulatory
effects of IL-10 are widely investigated, the mechanisms of alcohol-induced IL-10
production are still not yet well defined.
1.7 Progenitor/stem cell response in alcohol induced liver injury
Rodent and human studies have demonstrated that alcohol toxicity provides a
regenerative stimulus to the liver by; 1) inducing hepatocyte death, 2) inhibiting the
proliferative activity of adult hepatocytes and 3) inducing the compensatory expansion
of a liver progenitor cell/oval cell population (Diehl 2005;Natori et al. 2001;Ribeiro et
al. 2004;Wands et al. 1979;Zhang, Gong, & Minuk 2000). Furthermore, both animal
and human studies in chronic alcohol toxicity and liver injury have demonstrated that
this facultative liver stem cell/progenitor cell population is activated in the presence and
absence of inflammatory cell infiltrates and fibrogenesis and results in the regeneration
of hepatocytes and biliary epithelial cells (Diehl 2005;Diehl, Tan 2002;Thorgeirsson,
& Steer 1990;Roskams et al. 2003). These findings suggest that hepatic progenitor cell
differentiation becomes a critical component of the regenerative response in alcohol
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injured liver and that the requirement for differentiation is predicted to lengthen the
time needed to accomplish regeneration. Current understanding on how chronic alcohol
exposuremodulates the viability and differentiationofhepatic progenitor cells is limited
and virtually nothing is known about how alcohol affects the general mechanisms and
processes that regulate these progenitor cells in adult livers (Diehl 2005).
It is unclear whether these progenitor/oval cell populations in adult livers are derived
from an endogenous or a pluripotent circulating stem cell source (Menthena et al. 2004;
Petersen et al. 1999;Wang et al. 2003a;Wulf et al. 2003). Hepatic progenitor cells/oval
cells have some phenotypic traits that are typical ofBM stem cells and the liver harbours
many haematopoietic cell types (Omori et al. 1997;Petersen et al. 1998;Petersen et al.
1999). Rodent studies have demonstrated that BM derived hepatic oval/progenitor
cells could differentiate into hepatocytes in 2-AAF / partial hepatectomy (PH) and 2-
AAF/CCL, liver injury models which induce oval cell activation and proliferation (Oh
et al. 2007; Petersen et al. 1999). Data is however lacking in both animal and human
alcohol induced liver injury models on whether haematopoietic bone marrow stem
cells can repopulate and transdifferentiate into hepatic progenitor/oval cells and give
rise to hepatocytes.
Reports on the extent of peripheral blood HSC mobilisation in alcohol human induced
liver injury is limited to two studies with very small patient numbers and only looking at
patients with established alcohol cirrhosis and not acute alcoholic hepatitis. Kyriakou
et al found no evidence of elevated peripheral blood HSCs levels in three alcohol
cirrhotic patients whilst Di Campli et al failed to identify an increase in circulating HSCs
in two patients with decompensated liver disease (Di Campli et al. 2005;Kyriakou et
al. 2003). Studies on the extent of peripheral blood HSC mobilisation in acute alcohol
induced liver injury have not been reported and the degree of contribution to liver
repair from mobilised HSCs in this group of patients remains uncertain.
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1.8 Bone marrow stem cell therapy in liver injury
For patients with end-stage liver disease or acute liver failure, whole organ liver
transplantation is the only treatment ofproven benefit. However the increase shortage
of donor organs and the undesirable side effects of long-term immune suppressing
drugs restrict its application to many patients and thus necessitates the development
of alternative treatments. Whilst attention has been directed at developing alternative
strategies such as bio-artificial liver systems and cellular transplantation (using
hepatocyte suspensions), these still remain largely experimental. The application of
BM stem cell therapy in liver disease is an attractive modality for the regeneration
and reconstitution of damaged liver tissue, however it is still in its infancy with only a
couple of un-controlled feasibility studies available. BM stem cells have been utilised
to a greater degree in cardiology trials and demonstrating that therapy with adult BM
derived cells reduces infarct size and improves left ventricular function and perfusion
(Abdel-Latif et al. 2007; Erbs et al. 2007; Schachinger et al. 2006).
Intraportal administration of autologous CD 133"* bone marrow stem cells have been
used to augment liver regeneration in patients with liver tumours who underwent portal
vein embolisation to induce contralateral lobe hypertrophy prior to extensive partial
hepatectomy (Am Esch et al. 2005). In this study, the computerised tomography (CT)
scans demonstrated a 2.5 fold increase in size in the bone marrow-treated lobes when
compared with the non-bone marrow cell-treated controls. To date only a handful of
small phase 1 clinical trials have been reported in the literature involving autologous
BM stem cell (CD34+) infusions to patients with liver cirrhosis. Gordon et al conducted
a preliminary uncontrolled study on 5 cirrhotic patients of varying aetiology and
demonstrated an improvement in serum bilirubin and albumin levels 60 days after
portal vein or hepatic artery infusions of autologous CD34+ BM stem cells (Gordon et
al. 2006). Two other published clinical trials demonstrated an improvement in cirrhotic
patient clinical scores and biochemical parameters after autologous bone marrow cell
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infusion therapy (Terai et al. 2006; Yannaki et al. 2006). The mechanism that underlies
this improvement in not clear although it is speculated that HSCs may play a role in
stimulating endogenous hepatocyte proliferation in a paracrine fashion (Yannaki et al.
2006). Large scale controlled trials are however lacking and further trials are needed
to determine the effectiveness of stem cell infusion therapy in liver diseases.
1.9 Discussion
In this thesis alcohol induced liver injury was selected as the injury model of choice to
study human HSC mobilisation and hepatic recruitment based on the following reasons.
1) Alcohol toxicity inhibits adult hepatocyte proliferation and promotes a regenerative
stimulus to progenitor cells and potentially to BM derived pluripotent stem cells thus
providing a suitable injury model in which to study circuilating HSC responses and
hepatic recruitment. 2) Previous studies suggest that patients with inflammatory liver
diseases have elevated circulating HSCs (autoimmune hepatitis) as well as BM stem
cell contribution to liver repair (Hepatitis C). Acute alcoholic liver injury is another
form of inflammatory liver disease worth studying as this injury model would provide
further data to test the hypothesis that inflammatory liver injury promotes the release
of stem cells from the BM and recruits them to the liver for repair. 3) Cytokines and
inflammatory mediators such as IL-8, IP-10 and MCP-1 are thought to play a role in
the pathogenesis of alcohol mediated liver injury, yet these very same cytokines are
known to activate and induce the release ofHSCs thus providing a possible mechanism
to study and explain the regulatory process of BM stem cell release and recruitment
in this form of liver injury. 4) Alcoholic liver disease is the commonest cause of
cirrhosis in the Western world (Lieber 1993) and HSC multilineage plasticity has
raised hopes that such cells could, in the future, be utilised for the regeneration and
reconstitution of damaged liver tissue. This study will contribute to the understanding
of the mechanisms involved in recruiting stem cells into injured liver and provide
some clarification on how alcohol influences such processes, thus enabling us in the
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future to manipulate these cells to develop new treatments for liver diseases including
alcohol liver injury.
Current literature has demonstrated that ethanol exposure induces hepatocyte death and
inhibits the proliferative response of adult hepatocytes resulting in the accumulation of
hepatic stem cells within the liver as part of a regenerative response to injury although
the precise origin of these cells (hepatic vs. BM-derived) remains unclear. Hepatic
progenitor cells have some phenotypic traits that are typical of BM stem cells thus
highlighting the limitation of performing immunohistochemical analysis alone for
haematopoietic progenitor cells cell surface markers in alcohol injured liver tissue.
Published data suggests that HSC contribution to liver repair varies considerably in
various injury models however literature is lacking in both animal and human alcohol
induced liver injury on whether haematopoietic bone marrow stem cells can actually be
recruited into the injured liver and give rise to parenchymal cell lineages. Experimental
Chapters 2 and 3 aims to establish whether alcohol induced liver injury in humans
leads to the accumulation and expansion of progenitor stem cells within the liver and
to demonstrate that they are from a bone marrow HSC source.
Recently it has been recognised that BM derived stem cells can also give rise to hepatic
myofibroblasts, suggesting a functional contribution of BM stem cells to liver fibrosis
(Forbes et al. 2004; Russo et al. 2006). However no data is yet available in alcohol
induced liver injury whether BM derived stem cells contribute to either the hepatic
parenchymal or hepatic myofibroblast population. Chapter 3 will attempt to address
this unanswered question by assessing BM stem cell contribution to parenchymal and
non parenchymal eel 1 lineages in the alcohol injured liver and investigate the promotion
of endogenous hepatocyte proliferation by haematopoietic stem cells.
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Human studies have demonstrated elevated levels of peripheral blood HSCs in
patients with extensive liver resections, autoimmune hepatitis and in liver transplant
patients with ischaemic/reperfusion injuries. Data on the extent of peripheral blood
HSC mobilisation in human alcohol induced liver injury is limited to a few individual
patient cases with established alcohol cirrhosis but not to acute alcohol injury. Chapter
4 of this study would investigate and provide as yet unreported data on the extent of
HSC mobilisation in patients with acute alcohol injury and attempt to provide some
understanding on whether chemokine receptor expression of circulating HSCs are
important in regulating this mobilisation process.
The cytokines SDF-1, MMP-9, G-CSF, IL-8, MIG, IP-10, RANTES and MCP-1 have
been implicated in the mobilisation and migration of HSCs although their role in the
mobilisation and recruitment of HSC in clinical liver injury including alcoholic liver
disease has not yet been defined. In Chapter 5 we aim to study the role of these
inflammatory cytokines and chemokine axes in the mobilisation and recruitment of
HSCs in alcohol induced liver injury.
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Table 1
Tissue type Cell Line SDF-1 Expression
Bone Marrow Stromal Cell Lines
Tonsil Epithelial Cells in Tonsillar Crypt
Spleen Reticular Cells
Foetal Liver Mesothelial Cells, Biliary Epithelium, Ductal Plate
Adult Liver Biliary Epithelium
Lung Interstitial Cells
Cardiac Cardiac Myocytes
Brain Glial Cells, Cortical Neuronal Cells, Astrocytes
Muscle Skeletal Myocytes
Skin Epithelial Cells of Sweat Glands, Endothelial Cells, Pericytes, Dendritic Cells
Thymus Stromal Cells, Medullary Cells, Epithelial Cells
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Figure 1A: Release of HSCs from bone marrow into peripheral circulation mediated via SDF-1 concentration
gradient.
Figure IB: Release of HSCs into peripheral circulation enhanced via MMP-9 and IL-8.
Figure 1C: Recruitment of HSCs into injured liver mediated via SDF-1, HGF and SCF.
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CHAPTER 2
Hepatic stem cell content in human
alcohol induced liver injury
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2.1 Introduction
The significance of the contribution HSCs make to liver repair is contentious and
studies in both rodents and humans have demonstrated that ethanol exposure induces
hepatocyte death and results in the accumulation ofhepatic progenitors/oval cells within
the liver as part of a regenerative response to injury (Diehl 2005; Diehl, Thorgeirsson &
Steer 1990; Roskams et al. 2003). The precise origin of these progenitor cells (hepatic
vs. BM-derived) however remains controversial (Menthena et al. 2004; Petersen et
al. 1999; Wang et al. 2003a; Wulf et al. 2003). The aim of this chapter is to establish
whether alcohol induced liver injury leads to the accumulation and expansion of
progenitor stem cells within the liver which express haematopoietic stem cell markers
(CD34+ and c-kit+).
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2.2 Patients and methods
2.2.1 Patient details
In this study we analysed archival liver biopsy tissue specimens from 5 adult normal
control (NC) samples and compared them with 4 patients who had a history of
continuous alcohol consumption > 400gms/week, no clinical or serological evidence
of other causes of liver disease and had histological evidence of alcoholic hepatitis
(AH) on biopsy. The following histological criteria were used for the diagnosis ofAH
in this study; 1) Macrovesicular and microvesicular steatosis, 2) polymorphonuclear
cellular infiltrate, 3) intracellular accumulation of Mallory's hyaline/bodies and 4)
evidence of hepatocellular injury or necrosis.
Ethical approval for the use of archival liver biopsy tissue in this study was granted
by the Lothian Health Board Research and Ethics Committee (2003/R7GI/02).
Sample sizes for the control and AH patient groups was limited in this study due to
the restrictions placed by the ethical approval which only authorised access to a set
number of 75 pre-determined archival liver biopsy tissue samples of various hepatic
aetiologies. This meant that only 4 samples that fulfilled the criteria for alcohol related
hepatitis and 5 NC samples could be identified from this set. The anonymisation
process of the archival liver biopsies resulted in us being unable to retrieve further
patient/clinical details for 3 out of the 5 control specimens labelled as normal. These
NC samples labelled 1-3 were re-examined by a pathologist (Prof DJ Harrison) and
verified histologically that they appeared normal although we appreciate the limitations
ofnot having more clinical details to substantiate this clinically. The NC samples 4 and
5 were from pre transplant female donor livers aged 47 and 62 years respectively, both
died of subarachnoid haemorrhage and had no clinical history of pre-existing liver
disease. Both tissue samples were documented as normal on histopathology reporting.
The 4 AH liver biopsies specimens were from 1 female aged 52 and 3 male patients
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aged 38, 48, and 31 years respectively. Histopathological diagnosis of all liver samples
were based on the original pathological report and re-examined by a pathologist (Prof
DJ Harrison).
2.2.2 Immunohistochemistry for hepatic stem cells
To identify hepatic progenitor stem cells within the liver which express haematopoietic
stem cell markers (CD34+ and c-kit+), immunohistochemical staining was performed
sequentially on formalin fixed paraffin embedded (FFPE) tissue sections using
selected antibodies. A total of 4 consecutive sections were obtained from each biopsy
specimen. Each section was 3 micron thick, which is approximately half the thickness
of a nucleus, with neighbouring sections cut 3 microns apart. This procedure allowed
matching fields to be as close as possible to each other. Sections were dewaxed in
xylene for 10 minutes and rehydrated through graded alcohols (100%, 90% and 70%)
for 5 minutes each. All tissue sections were washed in distilled water for 5 minutes
and then microwaved in a pressure cooker for 4 minutes in 0.372gm/L EDTA (pH8)
solution. After microwave antigen retrieval the slides were allowed to cool in water
for 5 minutes and then blocked in 1% hydrogen peroxide for 15 minutes. Slides
were loaded into sequenza trays and washed with phosphate buffered saline (PBS).
Each slide was incubated for 30 minutes at room temperature with a single selected
primary antibody: CD31 mouse mAb (DakoCytomation, N1596), CD34 mouse mAb
(DakoCytomation, N1632), c-kit rabbit mAb (DakoCytomation, A4502) and mast cell
tryptase mouse mAb (DakoCytomation, M7052) at a dilution of 1:50, 1:50, 1:100 and
1:1600 respectively (seefigure 2).
The CD34, CD31 and mast cell tryptase labelled slides were washed and incubated
for 30 minutes at room temperature with a horseradish peroxidase (HRP) polymer-
conjugated detection antibody (DakoCytomation EnVision™ + System-HRP, K4006/
K4010). The c-kit labelled slides were washed and incubated for 30 minutes at room
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temperature in a 1:400 dilution of biotinylated swine anti-rabbit immunoglobulins
(DakoCytomation, E0353) followed by wash ofPBS and a further 30 minute incubation
at room temperature with an Avidin-Biotin HRP reagent (Vectastain Elite ABC kit,
PK6100). All slides were washed and incubated for 5 minutes at room temperature
with either diaminobenzidine (DAB) (DakoCytomation) or Vector® Nova RED™ as
substrate chromagens and then counterstained with Mayer's haematoxylin.
2.2.3 Microscopy and image processing
Each tissue section was stained with only a single antibody and sections were viewed
under a light microscope (Olympus B061, Japan). Sections were screened on low
power (200x) and areas of positive cell staining within portal tracts were photographed
at a magnification of 200x and 400x using a colour digital camera (Pixera Penguin
Pro 150ES, USA). Serial composite images of each photographed section were
pseudocoloured (green) and processed using image processing software (Adobe®
Photoshop® Software). CD34 is not exclusively expressed on haematopoietic stem
cells as vascular endothelial cells also express CD34 (Fina et al. 1990). Likewise
c-kit is expressed on haematopoietic progenitors and mast cells (Baghestanian et al.
1996). With Adobe® Photoshop® we were able to distinguish the true progenitor stem
cells from the endothelial (CD31+) and mast cells (mast cell tryptase) by digitally
subtracting the CD31+ and mast cell+ images from the composite images.
2.2.4 Cell counting
True progenitor stem cells were determined by counting c-kit+/mast cell" & CD347
CD3L cells from the processed digital images. Two separate assessors counted all
sections from the digital images taken at 400x magnification and were blinded to the
nature of the biopsy. The sections being measured contained a minimum of 3 portal




All statistics were performed on SPSS® 12.0 for Windows® software (SPSS Inc.
Chicago, IL). Results are expressed as the Mean with Standard Error of the Mean
(SEM) for individual column data. TheMann-Whitney U statistical test (non-parametric
significance) was used to determine whether the differences between the NC and AH
progenitor stem cell counts were significant. Results were considered significant when
p<0.05. The Cohen's kappa coefficient was used to determine inter-observer agreement
on true progenitor stem cell counts in the liver sections.
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2.3 Results
2.3.1 Increased numbers of stem cells (CD347CD3T and c-kit7mast cell ) are
seen in the livers of patients with alcoholic hepatitis
Immunostaining demonstrated that liver biopsies from AH patients contained a greater
number of stem cells/hepatic progenitor cells (CD347CD3T& c-kit+/mast cell ) in
the periductal region of the portal tracts as compared with NC. The CD347CD3 1
population was significantly elevated in the AH group (1.5 cells/triad/patient ± 0.58,
p<0.05) as compared to the NC group (0.24 cells/triad/patient ± 0.14). Likewise, the
c-kit+/mast cell" population of hepatic progenitor/stem cells was significantly elevated
in patients with AH (1.3 ± 0.33 cells/triad, p<0.05) as compared to the NC group (0.52
±0.18 cells/triad) (see figures 3-7). The ratio of CD34+ to c-kit+ stem cells in the AH
patient group was 0.87:1 and in the NC group 0.46:1. The Cohen's kappa coefficient
for the inter-observer agreement on true progenitor stem cell counts was 0.79.
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2.4 Conclusion
We have demonstrated that in alcohol induced liver injury there is an expansion of
hepatic progenitor cells within the liver expressing HSC markers and suggesting a
possible bone marrow source. We do however acknowledge the limitations of this
study in particular to the small sample size and the lack of clinical data available on
some of the normal control samples. Furthermore, hepatic progenitor cells express
a large panel of cell surface markers and share cell surface markers such as Thy-
1(CD90), c-kit, and CD34 with haematopoietic progenitor cells (Omori et al. 1997;
Petersen et al. 1998; Petersen et al. 1999) thus highlighting the limitation ofperforming
immunohistochemical analysis alone to distinguish the origins ofthese progenitor cells
(Bone marrow vs. endogenous). In Chapter 3 we aim to establish that circulating bone
marrow derived stem cells are recruited into the alcohol injured liver by performing
immunohistochemistry and fluorescent in situ hybridisation (FISH) for recipient derived
Y-chromosome on liver biopsies samples from cross-sex liver transplant patients who
subsequently developed evidence of alcohol induced liver injury.
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Figure 2
Figure 2: Immunohistochemical analysis for stem cells in liver sections.
Serial 3-pm-thick sections stained in the following sequence with primary antibodies. A) CD31-staining for
endothelial cells. B) CD34-staining for HSCs and endothelial cells. C) Mast cell tryptase-staining for mast
cells. D) C-kit-staining for HSCs and mast cells.
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Figure 3
Figure 3: Hepatic stem cell (CD347CD31" and c-kit7mast cell ) populations are elevated in AH patients.
Values are expressed as stem cells per portal triad per patient. Data represents mean values for each group ±
SEM. *p<0.05 compared with normal value.
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Figure 4
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Figure 4: Immunohistochemical analysis for
stem cells (CD34+/CD31") in AH liver sections.
A) Liver biopsy section from a patient with AH
stained for CD31 marker (brown). B) Image A with
green pseudocolouring demonstrating CD31 marker
(green). C) Sequential liver section from the same
patient with AH stained for CD34 marker (brown).
D) Composite image of sections B and C revealing
CD347CD31' hepatic progenitor cells in portal
triad (arrows, circle). E) Enlarged image ofCD347
CD31" hepatic progenitor cells in portal triad seen
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Figure 5: Immunohistochemical analysis for stem cells (c-kit+/mast cell ) in AH liver sections.
A) Liver biopsy section from a patient with AH stained for mast cells (brown). B) Image A with green
pseudocolouring demonstrating mast cells (green). C) Sequential liver section from the same patient with AH
stained for c-kit marker (brown). D) Composite image of sections B and C revealing c-kit"7mast cell hepatic
progenitor cells in portal triad (arrows). Original magnification: A-D, 400x. These images have been magnified
to demonstrate stem cell morphology.
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Figure 6
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Figure 6: Immunohistochemical analysis for stem
cells (CD34+/CD31) in normal liver sections.
A) Liver biopsy section from a normal control
stained for CD31 marker (brown). B) Image A with
green pseudocolouring demonstrating CD31 marker
(green). C) Sequential liver section from the same
normal control stained for CD34 marker (brown).
D) Composite image of sections B and C revealing
CD347CD3L hepatic progenitor cell in portal triad
(arrow). E) Enlarged image ofCD347CD31" hepatic
progenitor cell in portal triad seen in D (arrow).
Original magnification: A-D, 200x; E, 400x.
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Figure 7
Figure 7: Immunohistochemical analysis for stem cells (c-kit7mast cell") in normal liver sections.
A) Liver biopsy section from a normal control stained for mast cells (brown). B) Image A with green
pseudocolouring demonstrating mast cells (green). C) Sequential liver section from the same normal control
stained for c-kit marker (red). D) Composite image of sections B and C revealing c-kit+/mast cell" hepatic
progenitor cells in portal triad (arrows). Original magnification: A-D, 200x.
64
CHAPTER 3
Hepatic recruitment of bone marrow derived
stem cells in human alcohol induced liver injury
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3.1 Introduction
HSC contribution to liver repair varies considerably, with some of the observed variation
and putative mechanisms (transdifferentiation and fusion) being possibly related to the
type and severity of liver injury (Lagasse et al. 2000; Sakaida et al. 2004b; Terai et al.
2003). HSCs may also play a role in stimulating endogenous hepatocyte proliferation
in a paracrine fashion as evidenced by their contribution in rodent (Yannaki et al.
2005) and human studies (Terai et al. 2006). Recently it has been recognised that BM
derived stem cells can also give rise to hepatic myofibroblasts, suggesting a functional
contribution of BM stem cells to liver fibrosis (Forbes et al. 2004; Russo et al. 2006).
Data is however lacking in both animal and human alcohol induced liver injury models
on whether haematopoietic bone marrow stem cells can repopulate the liver and
transdifferentiate into hepatocytes and/or contribute to the myofibroblast population.
In the previous chapter (Chapter 2) we demonstrated that in alcohol induced liver
injury there is an expansion of hepatic progenitor cells expressing HSC markers and
suggesting a possible bone marrow source. In this chapter we wanted to establish that
alcohol induced liver injury, increases the hepatic recruitment of bone marrow derived
stem cells into the injured liver as well as to assess their contribution to parenchyma]
and non parenchymal cell lineages in the liver.
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3.2 Patients and methods
3.2.1 Patient details
In this study, cross-sex liver transplant patients who subsequently developed evidence
of alcohol induced liver injury were used to study the contribution of bone marrow
derived HSCs to parenchymal and non parenchymal liver cell lineages. Ethical approval
for the use of archival liver biopsy tissue in this study was granted by the Lothian
Health Board Research and Ethics Committee (LREC/2002/8/25). and informed
consent was obtained from patients to use the liver biopsy samples for experimental
purposes. We analysed archival liver transplant biopsies tissue samples taken at the
Royal Infirmary of Edinburgh from the period 1992 to 2003 from male patients who
were transplanted with female donor livers. From 90 archival cross-sex transplant
liver biopsy samples we could only identify 3 male cross-sex liver transplant patients
who subsequently developed evidence of alcohol induced liver injury ranging from
steatosis to steatohepatitis.
Patient characteristics, time of biopsy post transplant and histological diagnosis are
summarised in table 2. Histologically all 3 specimens showed features of alcohol
induced liver injury with no evidence of acute or chronic rejection. Patient 1 was a
59 year old male, non diabetic, BMI 27.8, with a history of alcohol consumption post
transplant and histology demonstrating a mild lobulitis with marked microvesicular
steatosis. No spotty necrosis or Mallory's hyaline was identified. No other cause for
fatty liver disease was identified. Patient 2 was a 50 year old male with a history of
alcoholic liver disease and chronic hepatitis C and was treated with 6 months treatment
of Interferon/Ribavirin therapy 36 months prior to liver transplantation. At the time
of liver transplantation his hepatitis C PCR was negative and remained negative at
the time of repeat liver biopsy. Unfortunately HCV Genotyping was not available in
the clinical notes, laboratory database or HCV patient treatment database. Histology
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demonstrated microvesicular steatosis, mild cholestasis related changes and giant
mitochondria favouring alcohol induced liver injury. Patient 2 was non diabetic, BMI
20.9 and no other cause for fatty liver disease was identified. Patient 3 was a 46
years old male, non diabetic, BMI 24.8 with a history of alcohol binge drinking post
transplant. Histology demonstrated severe mixed microvesicular and macrovesicular
steatosis, low grade peri-portal lymphocytic infiltrate, degeneration of centrilobular
hepatocytes and Mallory's hyaline consistent with alcoholic hepatitis. Routine day 7
post cross-sex liver transplant biopsies of these 3 patients were included as controls as
well as 3 normal pre transplant donor male liver controls and 3 normal pre transplant
donor female liver controls. The day 7 post transplant biopsies did not demonstrate
any significant cellular rejection or reperfusion injury. Histopathological diagnosis of
all liver samples were based on the original pathological report and re-examined by a
pathologist (Prof DJ Harrison).
3.2.2 Combined Immunohistochemistry and Fluorescent in situ Hybridisation
(FISH) for Y-chromosome
All liver sections were FFPE and cut sequentially 3 microns apart. Each section was
3 micron thick, which is approximately half the thickness of a nucleus, thus allowing
for matching fields to be as close as possible to each other. Slides were heated to
60°C for 20 minutes to melt wax, then washed in xylene 4 times for 10 minutes each
before dehydration through an ethanol series (100%, 95% and 70%). Slides were then
microwaved for 20 minutes in 0.1 mol/L citrate buffer, pH6.0 washed with PBS and
blocked in 1% hydrogen peroxide for 15 minutes. Slides were incubated for 30 minutes at
room temperaturewith one ofthe following antibodies; 1) HSCmarker: CD34mouse anti
human antibody 1:10 dilution (DakoCytomation, N1632), 2) biliary epithelial marker:
AE1/AE3 mouse antihuman antibody 1:50 dilution (DakoCytomation, M3515), and
3) myofibroblast marker: a-smooth muscle actin (a-SMA) mouse antihuman antibody
1:50 dilution (DakoCytomation, M0851). Slides were also incubated overnight at
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4°C with Ki-67 mouse antihuman antibody 1:400 dilution (DakoCytomation, M7240)
which is amarker for increased hepatocyte regeneration (Crary & Albrecht 1998). After
primary antibody incubation slides were washed and incubated for 30 minutes with an
HRP polymer-conjugated detection antibody (DakoCytomation EnVision™ + System-
HRP, K4006/K4010) or anAP detection antibody (DakoCytomation, K1396) followed
by incubation with either DAB (DakoCytomation) or Vector® Nova RED™(Vector
Labs, SK5100) as substrate chromagens. CD34 and a-SMA stained slides were co-
labelled with: CD31 mouse antihuman mAb (DakoCytomation, N1596) and CD34
mouse antihuman mAb (DakoCytomation, N1632) at a 1:10 dilution followed by AP
detection antibody (DakoCytomation, K1396) and Vector® Nova RED™ (Vector
Labs, SK5100).
One microgram human Y-chromosome DNA was labelled with digoxigenin 11-dUTP
(Roche, 1363905), by nick translation. Unincorporated nucleotides were removed
by centrifugation through Quick Spin G50 Sephadex columns (Roche, 1273973).
Specific activity of the probes was performed by dotting onto nitrocellulose filters
using anti-digoxigenin-alkaline phosphatase Fab fragments (Roche, 1093274). We
then used a BCIP/NBT kit (Vector, SK 5400), which produces the purple change on the
filter, which we then compared with known standards (DNA ofknown concentrations).
After thorough washing the liver sections were denatured for 3 minutes at 75°C in
70% formamide/2x SSC, plunged into ice-cold 70% ethanol for 3 minutes, dehydrated
through an alcohol series and air-dried. Two hundred nanograms labelled human Y-
chromosome DNA, lOpg Cotl DNA (repetitive DNA sequences) and 5pg sonicated
salmon sperm DNA were denatured together for 5 minutes at 70°C in 50% deionised
formamide, 50% dextran sulphate, 2x SSC and 1% Tween 20. Thereafter the
hybridisation mix and probe were re-annealed at 37°C for 15 minutes. lOpl of mix
(hybridisation mix and probe) was pipetted onto each slide and allowed to hybridise
overnight at 37°C. Slides were washed 4 times for 3 minutes in 2x SSC at 45°C and
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then successively incubated for 30 minutes at 37°C with a 1:500 dilution of a sheep
avidin Fluorescein Isothiocynate (FITC) antibody (Roche), followed by a further 30
minutes with a 1:100 dilution of anti avidin biotin antibody and then a final 30 minutes
with a 1:500 dilution of a sheep avidin FITC antibody (Roche). The slides were washed
thoroughly in 4x SSC/0.1% Tween 20 between incubations. Slides were mounted in
Vectashield (Vector Laboratories) containing lg/mL 4, 6-diaminidino-2-phenylindole
(DAPI) counterstain.
Hepatocyte immunostaining quality was compromised by the in situ hybridisation
processing methods which affected the hepatocyte epitopes in these liver sections,
hybridization process, thus we employed amethod ofprocessing the 3 micron thick serial
sections sequentially for Y-chromosome FISFI followed by immunohistochemistry for
Hep Par 1 hepatocyte mouse antihuman mAb 1:50 dilution (DakoCytomation, M7158)
as per above protocol.
3.2.3 Microscopy and image capture
For light microscopy, an Olympus B061 microscope was used and images captured
with a digital camera (Pixera Penguin Pro 150ES, USA).For fluorescent microscopy,
slides were visualised using a Zeiss Axioplan 2 fluorescence microscope equipped
with a triple bandpass filter (Chroma #83000). Greyscale images were collected with
a cooled charge-coupled devise camera (Quantix Corp) and analysed using custom
IPLab scripts. Image processing was performed using Adobe® Photoshop® software.
3.2.4 Cell counting
Y-chromosome positive nuclei were counted from contiguous fields at x 400
magnification and matched to the corresponding immunostaining for CD34 / CD31 /
AE1/AE3 / a-SMA/ and Hep Par 1 markers according to the location and architecture
of the tissue on the slide. Counting of all Y-chromosome positive nuclei in a 3 micron
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thick section was not possible because a significant proportion of Y-chromosome will
be missed by the section in any particular cell. Thus a correction factor was obtained
by counting all nuclei from normal male liver control tissue and expressed as a fraction
ofY+/total number of nuclei. Analysis of the normal male liver control group identified
only 38.46% of all nuclei as being Y-chromosome positive and a correction factor of
2.60 was applied to all Y+ cell counts in order to obtain a true estimate ofmale recipient
derived cells in each section. The above methodology has commonly been applied in
other similar studies (Theise et al. 2000b;Forbes et al. 2004). Both corrected and
absolute Y+ cell counts were analysed for statistical purposes in order to ensure that
any errors that may have occurred in the assessment of Y-chromosome detection was
not exaggerated and multiplied.
To evaluate the percentage of positive staining Ki-67 hepatocytes, 5 to 10 random
fields were selected per liver biopsy slide and Ki-67+ hepatocytes were counted under
x400 magnification. A single assessor counted all sections from the digital images and
was blinded to the nature of the biopsy.
3.2.5 Statistics
All statistics were performed on SPSS® 12.0 for Windows® software (SPSS Inc.
Chicago, IL). Results are expressed as the Meanwith Standard Error oftheMean (SEM)
for individual column data. The Wilcoxon Matched Pairs Signed Ranks test (non-
parametric paired testing significance) was used to determine whether the differences
between the day 7 post transplant biopsies with the subsequent alcohol liver injury
biopsies were significant. Results were considered significant when p<0.05.
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3.3 Results
3.3.1 A significant proportion of CD34+ and a-SMA+ cells in alcohol injured
livers are derived from circulating bone marrow cells
To identify the source of the intrahepatic CD34+ stem cells in the context of alcohol
induced liver injury, we studied cross sex liver transplant biopsies from male patients
with evidence of alcohol induced liver injury using combined FISH for Y-chromosome
and immunohistochemistry for CD347CD3 Tcells. Analysis of the normal male liver
control group identified Y-chromosome positive nuclei whilst no Y-chromosome
positive nuclei were detected in any of the female donor livers prior to transplantation
(3/3 normal histology) (seefigure 8).
There were increased Y+ recipient CD34+ cells (expressed as a % of total cells) in the
cross-sex liver grafts from patients with alcohol induced liver injury than in control
patients who had a routine day 7 post transplant protocol liver biopsy (0.706 ± 0.233%
vs. 0.036 ± 0.02065% p<0.05).When this figure was corrected by the correction factor
of2.60 (see methodology) then the Y+ recipient CD34+ cell count in the alcohol injured
cross-sex liver grafts compared with routine day 7 post transplant protocol liver biopsy
was 1.834 ± 0.605% vs. 0.094 ± 0.054%, p<0.05. These Y+/CD34+cells were identified
within the perisinusoidal, intrahepatic and periportal regions of the biopsies whilst none
were seen within the biliary tracts (see figures 9-10). These Y+/CD34+ cells did not
co-stain for the endothelial cell marker CD31 suggesting they were true BM derived
stem cells and not donor derived endothelial cells (see figure 11). Further analysis in
the 3 cross-sex liver grafts samples with alcohol induced liver injury demonstrated
that 7.79%, 3.03% and 10.3% of the myofibroblasts (a-SMA+) were Y+. When this
figure was corrected by the correction factor of 2.60 then 20%, 7.9% and 26.8% of the
myofibroblasts seen were of BM origin (see figures 12-13), with the value of 26.8%
being found in the Patient 3 sample with the most pronounced histological changes.
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Notably the proportion of a-SMA+cells that co-stained for CD34 was higher in cross-
sex donor liver grafts with alcohol induced as compared with controls (5.025 ± 0.621%
vs. 0.494 ± 0.197%, p<0.05) (see figures 14-15). We were unable to identify any Y+
biliary epithelial cells or hepatocytes in these biopsies suggesting that BM derived
stem cells did not contribute to hepatocyte or biliary cell repair in alcohol induced liver
injury (seefigure 16).
3.3.2 Increased stem cell numbers in alcohol injured livers are not associated
with an alteration in endogenous hepatocyte proliferation.
Liver regeneration in the cross-sex liver biopsy samples was assessed by
immunohistochemical analysis of Ki-67 staining. We did not detect any increase in
the percentage of Ki-67+ staining hepatocytes in the cross-sex liver grafts with AH
as compared with controls (2.088 ± 0.410% vs. 1.884 ± 0.285%), suggesting that
HSCs recruited into the liver do not promote endogenous hepatocyte proliferation in a
paracrine fashion (seefigures 17-18). Results for combined FISH and immunostaining
analysis are summarised in table 3.
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3.4 Conclusion
From this study we have demonstrated that human BM derived stem cells are recruited
into the liver during alcohol induced liver injury and that a proportion ofmyofibroblasts
post liver transplantation are derived from the BM in whom alcohol injury has
recurred, consistent with previous observations post transplantation in viral hepatitis.
Furthermore, it is also possible that a population of CD34+ cells within the liver were
contributing to the recipient derived myofibroblast population in alcohol liver injury.
Whilst there was an increase in the CD34+ stem cell population within the liver there
was no evidence of increased hepatocyte proliferation nor evidence of BM stem cell
contribution to parenchymal cell lineages in the alcohol injured liver. We appreciate
that the number of patients studied to assess the contribution of BM stem cells to
hepatic myofibroblasts and progenitor populations is small, although recurrence of
alcohol induced liver injury is an uncommon clinical feature in post transplant patients
thus limiting the availability of such samples to study.
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Table 2
Patient 1 Patient 2 Patient 3
Age of recipient (years) 59 50 46
Aetiology for transplantation ALD HCV & ALD ALD
Blood group of recipient o+ A+ A+
Sex of donor Female Female Female
Age of donor (years) 47 57 62
Blood group of donor o+ A+ A+
Type of liver transplant Cadaveric Cadaveric Cadaveric












Table 2: Characteristics of liver transplant patients.
All liver transplant patients were male. ALD: alcoholic liver disease; HCV: hepatitis C virus.
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Table 3
Patient 1 Patient 2 Patient 3
Y7CD34+ cells expressed as a
% of total cells per section
2.51% (0.97%)* 0.63% (0.24%)* 2.37% (0.91%)*
% of Y7a-SMA+ cells 19.9% (7.8%)* 7.9% (3.03%)* 26.8% (10.3%)*
% of CD347a-SMA+ cells 6.10%** 5.03%** 3.95%**
% of Y7Hepatocyte+ cells 0% 0% 0%










Table 3: Results of combined FISH and immunostaining.
The mean proportion ofY+ chromosome cells was 38.46% in the male control section and 0.0% in the female control
sections. * Counts unadjusted for correction factor 2.6. ** Dual immunohistochemistry data without FISH for Y-
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Figure 8: FISH analysis for y chromosome in liver biopsies from male and female controls.
A-C) Liver biopsies from male controls demonstrating y chromosome with direct in situ hybridisation (green,
arrows). D) Liver biopsy from female control demonstrating the absence of y chromosome. Direct in situ
hybridisation. Original magnification: A-D, 600x.
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Figure 9
Figure 9: FISH and immunohistochemical analysis for recipient CD34+ cells in cross-sex donor liver
grafts with alcohol injury.
A) Liver biopsy from a male patient transplanted with a female liver and subsequently developed alcohol
induced steatohepatitis. Direct in situ hybridisation for y chromosome (green, arrow). B) Image A combined
with immunohistochemistry for CD34 (brown, arrow), CD31 staining was negative. C-D) Liver biopsy from a
male patient with a cross-sex liver graft and alcohol induced microvesicular steatosis. Direct in situ hybridisation
for y chromosome (green, arrow) combined with immunostaining for CD34 (brown, arrow), CD31 staining
was negative. Original magnification: A-D, 600x.
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Figure 10
Figure 10: FISH and immunohistochemical analysis for recipient CD34+ cells in cross-sex donor liver
grafts with alcohol injury.
A-B) Liver biopsy from a male patient with a cross-sex liver graft and alcohol induced microvesicular steatosis.
Direct in situ hybridisation for y chromosome (green, arrows) combined with immunostaining for CD34
(brown, arrows), CD31 staining was negative. Original magnification: A-D, 600x.
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Figure 11
Figure 11: Immunohistochemistry for CD31+and CD34+ cells in cross-sex donor liver grafts with alcohol
injury.
A) Immunofluorescence for CD31 (red, arrows) demonstrating hepatic venule CD31+ endothelial cells in
a liver section from a male cross-sex liver graft patient with alcohol induced steatohepatitis. B) Image B
demonstrating co-staining for CD34+ (brown) / CD31+ (red, arrows). Original magnification: A-B, 600x.
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Figure 12
Figure 12: FISH and immunohistochemical analysis for recipient myofibroblasts (a-SMA+) cells in cross-
sex donor liver grafts with alcohol injury.
A) Liver biopsy from amale patient transplantedwith a female liver and subsequently developed alcohol induced
microvesicular steatosis. Direct in situ hybridisation for y chromosome (green, arrow). B) Image A combined
with immunohistochemistry for a-SMA+ demonstrating recipient derived myofibroblasts (brown, arrow).
C-D) Liver biopsy from a male patient with a cross-sex liver graft and alcohol induced steatohepatitis. Direct
in situ hybridisation for y chromosome (green, arrows) combined with immunostaining for a-SMA+ (brown,
arrows). Original magnification: A-D, 600x.
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Figure 13
Figure 13: FISH and immunohistochemical analysis for recipient myofibroblasts (a-SMA+) cells in cross-
sex donor liver grafts with alcohol injury.
A-B) Liver biopsy from a male patient with a cross-sex liver graft and alcohol induced steatohepatitis. Direct
in situ hybridisation for y chromosome (green, arrows) combined with immunostaining for a-SMA+ (brown,
arrows). C-D) 3-pm-thick sequential liver sections from the same male patient with a cross-sex liver graft and
alcohol induced steatohepatitis demonstrating recipient y chromosome (green, arrows and circles) in the same
region as immunostaining for a-SMA+ (brown, circles). Original magnification: A-B, 600x, C-D, 400x.
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Figure 14
Figure 14: CD34+ cells are capable of becoming myofibroblasts (a-SMA+) in alcohol induced liver
injury.
A) Co-staining for CD34+ (red) / a-SMA+ (brown) cells in liver section from a male patient with a cross-sex
liver graft and alcohol induced steatohepatitis (arrows), note that the CD34+/a-SMA+ cells are localised within
the inflammatory infiltrate and in close proximity to fibrous tissue. B) Green pseudo colouring of image A
accentuating co-staining for CD34+ (green) / a-SMA+ cells (brown, arrows). C) Co-staining for CD34+ (red)
/ a-SMA+ (brown) cells in liver section from a male patient with a cross-sex liver graft and alcohol induced
microvesicular steatosis (arrows). D) Green pseudo colouring of image C accentuating co-staining for CD34+
(green) / a-SMA+ cells (brown, arrows). Original magnification: A-B, 200x; C-D, 400x. These images have
been magnified to demonstrate myofibroblast morphology.
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Figure 15
Figure 15: Immunohistochemical analysis for CD34+/a-SMA+ cells in day 7 post cross-sex liver transplant
biopsies (control).
A) Co-staining for CD34+ (red) / a-SMA+ (brown) cells in liver section from a male patient with a cross-sex
liver graft. B) CD34+ (red) / a-SMA+ (brown) cells identified in peri-portal region of liver biopsy from a
male patient with a cross-sex liver graft (arrows). Original magnification: A, 50x; B, 400x. Image B has been
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Figure 16: Recipient hepatocytes and biliary epithelial cells (CK AE1/AE3) were not identified in cross-
sex donor liver grafts with alcohol injury.
A) Liver section from a male patient transplanted with a female liver and subsequently developed alcohol
induced steatohepatitis. Recipient y chromosome was not detected by direct in situ hybridisation. B) 3-gm-
thick sequential liver section from the same male patient in image A stained for human hepatocyte marker Hep
Par 1 (brown). Both image A and B represent the same region of biopsy tissue. C) Liver biopsy from a male
patient with a cross-sex liver graft and alcohol induced steatohepatitis stained for biliary marker CK AE1/AE3
(red, arrow). D) Liver section from a male patient transplanted with a female liver and subsequently developed
alcohol induced steatohepatitis. Recipient y chromosome was not detected in the biliary epithelium by direct in




Figure 17: Immunostaining for Ki-67 in cross-sex donor liver grafts with alcohol injury.
A-B) Liver section from a male patient transplanted with a female liver and subsequently developed alcohol




Figure 18: Immunohistochemical analysis for Ki-67 in day 7 post cross-sex liver transplant biopsies
(control).
A-B) Liver section from a male patient transplanted with a female liver. Staining for Ki-67 indicates hepatic
parenchymal cell proliferation (brown, arrows). Original magnification: A-B, x400.
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CHAPTER 4
Mobilisation of circulating haematopoietic
stem cells in human alcohol induced liver injury
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4.1 Introduction
In the previous chapter (Chapter 3) we demonstrated that human BM derived HSCs
are recruited into the alcohol injured liver. As part of this recruitment process, we aim
in this chapter (Chapter 4) to establish that alcohol induced liver injury mobilises
human bone marrow derived HSCs into the peripheral circulation without altering
their stem cell potential. Previous human studies have demonstrated increased levels
of circulating human HSCs in response to a systemic injury, surgical trauma and in
patients following extensive liver resection (Grzelak et al. 1998; Lamming et al. 2003;
Paczkowska et al. 2005; De Silvestro et al. 2004). The extent to which these peripheral
blood HSCs are mobilised into the circulation of patients with other types of liver
injury in particular alcohol induced injury has not been well studied.
The chemokine SDF-1 and its receptor CXCR4, play an important role in the
mobilisation of human and rodent HSCs from BM both in the absence and presence
of liver injury (Kollet et al. 2003; Lapidot & Petit 2002; Petit et al. 2002; Terada
et al. 2003). Their role in clinical liver injury however has not been studied. The
chemokines MIG and IP-10, which mediate their effect through chemokine receptor
CXCR3, are important in recruiting T lymphocytes into the injured liver as well as
playing a crucial role in CD34+ HSC adhesion and therefore could also be important in
the recruitment of HSCs in liver disease (Jinquan et al. 2000; Nanji et al. 1999).
In this chapter we wanted to establish if the CXCR3 and CXCR4 chemokine receptor
profiles of circulating HSCs are important in regulating the mobilisation process in
alcohol induced liver injury.
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4.2 Patients and methods
4.2.1 Patient details
In this study, blood samples from patients with AH were used to establish whether
human BM derived HSCs are mobilised into the peripheral circulation in alcohol
induced liver injury. Blood samples were collected from healthy volunteer controls and
from patients attending the Royal Infirmary of Edinburgh from October 2002 to June
2004 and gave informed consent to use the blood samples for experimental purposes.
Ethical approval for the study was granted by the Lothian Health Board Research and
Ethics Committee (LREC/2000/4/187). Patients with AH, chronic abstinent alcoholic
cirrhosis, primary biliary cirrhosis (PBC), untreated hepatitis C virus (HCV) and acute
paracetamol injury were included in this study. Blood samples from AH patients were
taken within the first week of admission and for acute paracetamol injury patients
taken within 76 hours of admission. All other patient blood samples were taken at
routine out patient clinic visits. Haematological and biochemical laboratory data from
all patients were also collected. Blood samples from 15 AH patients (7 Female, 8
Male, Mean age 49yrs), 7 acute paracetamol injury patients (2 Female, 5 Male, Mean
age 35yrs), 8 chronic abstinent alcoholic cirrhosis patients (1 Female, 7 Male, Mean
age 48yrs), 7 untreated HCV patients (2 Female, 5 Male, Mean age 44yrs), 6 PBC
patients (all Female, Mean age 58yrs) and 12 normal healthy volunteers (6 Female, 6
Male, Mean age 31 yrs) were obtained. The mean age, male to female ratios, numbers
(n) and biochemical parameters for all groups are summarised in table 4.
Blood samples fromAH patients were included ifthey fulfilled the following parameters:
1) Recent alcohol abuse (>400gm/week), 2) Jaundice (serum bilirubin >50pmol/l), 3)
one or more of the following criteria: hepatomegaly, pyrexia, leukocytosis and 4) No
previous documented history of alcoholic cirrhosis. We did however accept that in this
AH patient group there would be a proportion of patients with established alcoholic
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cirrhosis on admission even though it may have not been previously documented or
identified. Exclusion criteria were concurrent sepsis, corticosteroid treatment, recent
gastrointestinal bleeding and significant co-morbidity such as cardiorespiratory failure
or neoplasia.
All patients with AH had an admission prognostic formula calculated known as
Maddrey's discriminant function (DF) (Maddrey et al. 1978). This formula has been
widely used as a tool to assess severity ofAH and has been validated in several studies:
DF = 4.6 x (PT patient - PT control) (s) + serum bilirubin (pmol/1) / 17.1. Values of
more than 32 effectively identify patients whose one-month mortality is 50%. Eight
patients with significant AH (Maddrey's DF >32) in this study were all treated with
Pentoxifylline, a non-selective phosphodiesterase inhibitor that has been shown to
decrease TNF-a gene transcription (Strieter et al. 1988) as well as the production of
other cytokines and chemokines including interleukin-1 (3 (IL-1 (3), 1L-6, interferon-y
(IFN-y), IL-8, NE, MCP-1 and RANTES (Gutierrez-Reyes et al. 2006;Morgan &
McClain 2000a;Neuner et al. 1994;Oka et al. 1991;Seldon ct al. 1995).
We did not exclude these patients from our study as it would not only limit our sample
size but by doing so our data would be skewed and less representative of the spectrum
of severity ofAH patients that is seen clinically. Pentoxifylline is not known to directly
inhibit HSC mobilisation although it does modify the host immune responses and is
likely to have an effect on cytokine levels. We acknowledge this fact as a limitation of
the study and will address these limitations further in the discussion Chapter 6.
4.2.2 Peripheral blood CD34~ cell enumeration and chemokine receptor
profile
Peripheral blood samples (40mls) was collected into hcparinised syringes and
prepared immediately. Light density fraction mononuclear cells were isolated from
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the peripheral blood by centrifugation using 1,077g/l Histopaque® solution (Sigma
Diagnostics, St Louis, MA, USA, 1077) in a 50ml Leuco Sep tube containing filter
(Greiner Bio-One GmbH).
The light density monolayer was separated and incubated with red cell lysis buffer
for 5 minutes. The sample was then washed with sterile PBS until visibly clear of
erythrocytes. Red cell lysis buffer was prepared with NH4C1, NaHC03, disodium
EDTA and made up to pH7.4 with NHC1 or Na2OH.
Cells were counted with an inverted microscope (Zeiss Telaval 31, Germany) for correct
antibody concentrations and the mononuclear cell enriched suspension was labelled
with mouse anti-human CD45: R-phycoerythrin- cyanine dye 5 (RPE-CY5) (Serotec
Ltd, Oxford, UK, MCA 1719C), mouse anti-human CD34: Fluorescein Isothiocynate
(FITC) (BD Biosciences, San Diego, CA, USA, 555821), mouse anti-human CXCR4:
phycoerythrin (PE) (R&D Systems Europe Ltd, Oxon, UK, FAB 170P) and mouse anti-
human CXCR3: PE (R&D Systems Europe Ltd, Oxon, UK, FAB160P) conjugated
monoclonal antibodies. The labelled cells were incubated at 4°C for 30 minutes in the
dark and then washed twice with PBS (5 minutes at 500g) before being resuspended in
500pl PBS for analysis by flow cytometry.
A reliable marker for circulating haematopoietic stem and progenitor cells has led to
the development of the single-platform International Society for Haemotherapy and
Graft Engineering (ISHAGE) flow cytometric assay which quantitates such cells on
the basis of their expression of CD34 (Sutherland et al. 1996). This single-platform
ISHAGE method for CD341 cell enumeration has been internationally validated and is
widely used for evaluation ofgraft adequacy ofperipheral blood and bone marrow stem
cell grafts. Using the FACS VANTAGE® flow cytometry sorting machine, CD34+ cells
were quantified as a percentage of low side scatter mononuclear cells using ISHAGE
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flow cytometry guidelines (Sutherland et al. 1996) which uses forward/side scatter
gating followed by gating on the marker CD45 and CD34. The first stage of analysis is
to plot the events on a forward scatter vs. side scatter dotplot and to select a gate around
the low side scatter population ofmononuclear cells which predominantly comprise of
lymphocytes which excludes debris, platelets, macrophages, monocytes and unlysed
erythrocytes. In the second stage, the selected mononuclear cell population is then
displayed on a CD45 vs. CD34 dotplot and the cluster of CD347CD45 intermediate
events detected are gated. Finally the CD347CD45 intermediate population selected
is then quantified as a percentage of the total events gated in the first stage of analysis
i.e. low side scatter mononuclear cells (see figure 19). The percentage of CD34+ cells
expressing CXCR3/CXCR4 as well as CXCR3/CXCR4 receptor density was also
quantified by flow cytometry.
4.2.3 Colony forming unit cell assays
To prepare cells for culture, Iscoves Modified Dulbecco's Media (IMDM) (Stem Cell
Technologies, Vancouver, BC, Canada, 07700) was used for all washes and dilutions
instead ofPBS. After CD347CD45+cell quantification as described above, the CD347
CD45+ cells from AH patients and NC were sorted using the FACS VANTAGE® flow
cytometry sorting machine and collected into IMDM containing Eppendorf tubes at
a concentration of 4.5 x 103 cells/mL. Cells were added to a methylcellulose culture
tube, consisting of 1% methylcellulose in IMDM, 30% foetal bone serum, 1% bovine
serum albumin, 10 4M 2-mercapoethanol, 2mM L-glutamine, 50ng/ml stem cell factor,
lOng/ml GM-CSF, lOng/ml IL-3, 3 units/ml erythropoietin (Methocult™, StemCell
Technologies, Vancouver, BC, Canada, GF H4434) and vortexed. With a syringe and
blunt ended needle, 2.5ml of this solution was drawn up and 1.1ml added into two
40mm x 10mm Petri dishes (StemCell Technologies Inc. Vancouver, BC, Canada),
producing a final cell culture concentration of 450 cells per plate. All cultures were
performed in duplicate and incubated at 37°C in a 95% humidified 5% CO, atmosphere
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for 14 days at which point all cell cultures would be terminally differentiated. Burst-
forming unit-erythroid (BFU-E), colony-forming unit granulocyte, macrophage (CFU-
GM) and colony-forming unit granulocyte,erythroid, macrophage,megakaryocyte
(CFU-GEMM) colonies together referred to as colony forming units (CFUs) were
counted after 14 days using a phase contrast inverted light microscope (Zeiss Telaval
31, Germany). In order to identify the possibilty that other progenitor cells different
from the CD347CD45+ identified in the AH and NC groups were also present in the
circulating blood we collected corresponding CD34VCD45+ cell fractions and grew
them using the same culture conditions.
4.2.4 Statistics
All statistics were performed on SPSS® 12.0 for Windows® software (SPSS Inc.
Chicago, IL, USA). Results are expressed as the Mean with Standard Error of the Mean
(SEM) for individual column data. Differences between groups were analysed with
a one way analysis of variance (ANOVA) test with post-hoc Dunnets test to compare
each group with normal controls. Results were considered significant when p<0.05.
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4.3 Results
4.3.1 Circulating CD34+ HSC levels are elevated in patients with alcoholic
hepatitis and retain their stem cell properties
No significant difference in the sex or age distribution was demonstrated between the
AH and the NC group. Circulating CD34+ HSCs levels were significantly elevated
in patients with AH (0.195 ± 0.063%, p<0.05) when compared with the NC group
(0.067 ± 0.01%) (see figure 20). There was no significant difference in the CD34+
values for either the acute paracetamol liver injury (0.068 ± 0.013%) or chronic liver
injury groups (0.08 ± 0.014%) when compared with the NC (see figure 20). This
would indicate that the rise in circulating CD34+ values was a specific response to AH,
rather than a non-specific response to other forms of liver injury. The total lymphocyte
counts were not significantly different in the AH group (1.216 ± 0.146 x 109/1) when
compared with the NC (1.55 ± 0.095 x 1071), chronic liver injury (1.317 ± 0.151 x
1071) and acute paracetamol liver injury groups (0.83 ± 0.182 x 1071). The circulating
neutrophil counts were significantly elevated in AH patients (9.39 ± 1.96 x 1071,
p<0.05) as compared with the NC (3.24 ± 0.36 x 1071) and other types of liver injury.
The mean Maddrey score which is a prognostic score of severity for patients with AH,
was 52.507 ± 11.225 consistent with clinically severe AH. Patient profile, admission
Maddrey Score, peripheral blood CD34+ count and 28 day survival for patients with
AH are tabulated in table 5.
Although the mean Maddrey score in the AH patient group was 52.5 and indicative
of severe disease (with expected 28 day mortality >50%) only 3 patients (20%) in
the AH study cohort were deceased suggesting that this patient group studied was
not reflective of the natural history ofAH. A possible explanation for this lower than
expected mortality rate in our study cohort could be that patients with sepsis, recent
gastrointestinal bleeding and significant co-morbidities were excluded and thus omitting
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the common causes for morbidity and mortality in such patients with severe AH. We
noted that the 12 surviving AH patients had higher levels of circulating CD34+ HSCs
(0.24 ± 0.08%) when compared with the 3 AH patients who had died (0.07 ± 0.03%).
However as patient numbers in the deceased AH group were too small for comparison
we could not draw any firm conclusion regarding HSC mobilisation and its effect on
the subsequent course of illness in AH patients.
To determine the 'sternness' of these mobilised cells, we performed CFU assays of
the CD34+ isolated cells. The CFU frequency per plate (containing 0.45 x 103 CD34+
cells) in AH and NC are shown infigure 21. In the AH patients there were significantly
higher levels of CD34+/CD45+ total CFU counts as compared with NC HSCs (154 ±
38 vs. 44.75 ± 28.4, p<0.05). Interestingly, there was also a significantly higher level
of CD34 /CD45+ total CFU counts in the AH group as compared with NC (see table
6). In both patient groups the cell assays demonstrated mature and multiple lineage
CFUs (see figure 22).
4.3.2 CD34 mobilisation in alcoholic hepatitis is not associated with
alterations in the cell CXCR3/CXCR4 receptor expression
There was no significant difference in either the percentage of CD341 expressing
CXCR4 or receptor density / cell in the AH group (86.66 ± 4.12% & geometric mean
[GM] 71.71 ± 21.52 respectively) when compared with the NC (80.36 ± 6.6% & GM
63.35 ± 21.4), acute paracetamol injury (83.46 ± 4.14% & GM 56.65 ± 16.73) and
chronic liver injury groups (80.08 ± 2.47% & GM 64.57 ± 12.07) (see figure 23).
Furthermore, no significant difference was demonstrated in either the percentage of
HSCs expressing CXCR3 or receptor density / cell in the AH group (82.9 ± 5.13% &
GM 57.9 ± 20.6 respectively) when compared with NC (70.18 ± 9.4% & GM 37.0 ±
8.61) acute paracetamol injury (73.32 ± 7.12% & GM 53.87 ± 12.43) and chronic liver
injury groups (70.635 ± 3.995% & GM 45.178 ± 8.453) (seefigure 24).
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Although no significant difference was identified in CXCR3 and CXCR4 receptor
expression on circulating HSCs, their functionality was not assessed. It is possible that
the CXCR3 and CXCR4 receptor function on circulating CD34+ cells could have been
altered in the all types of liver injury despite any changes seen in receptor expression.
We did not pursue CXCR3 or CXCR4 receptor functional experiments such as Boyden
chamber chemotaxis assays and/or intracellular free calcium fluorimetry assays due to
the limited number of CD34+ cells available from each sample to do these assays.
Eventhough we identified a significant increase in circulating CD34+ HSCs in AH
patients, the relative concentration of circulating CD34+ cells in peripheral blood is
still low ranging from a mean of 0.067% in NC to 0.195% in AH patients. At these
low concentrations, a 40ml peripheral blood sample (the maximum amount approved
by ethics) would only yield between 5 x 103 to 11 x 103 CD34+ cells when collected
using the FACS VANTAGE® flow cytometry sorting machine. The cell culture assays
alone required 4.5 x 103 cells/mL per sample, thus leaving no surplus cells available
for us to perform the functional assays which required a minimum of 24 x 103 for the




Our study demonstrated that in patients with acute alcoholic hepatitis circulating
CD34+ HSCs levels were elevated as a response to liver injury and retained their true
stem cell properties. We failed to demonstrate a similar significant elevation in cir¬
culating CD34+ cell counts in other acute or chronic liver injury groups studied. The
CXCR3 and CXCR4 receptor expression/profiles were unaltered on these circulating
CD34+ stem cells although cell surface receptor functionality was not assessed. All
blood samples were non serial time course samples and patients with severe AH were













Mean Age in years 49 ±3.06 35.29 ±3.73 50 ±2.10 31.58 ± 3.16
Male:Female Ratio 1:0.875 1:0.4 1:0.75 1:0.875








288.33 ±59.16 114.14 ±23.57 46.95 ±12.04 20.2 ±4.88
Serum ALT
concentration (IU/1)*
53.87 ±10.01 4610.86 ±568.15 50.1 ±8.13 24.36 ±4.23
Serum albumin
concentration (g/1)*
28.47 ±1.04 31 ±1.90 37.05 ±1.81 46 ±1.62
Prothromin time
(seconds)*
21.13 ±7.15 35.14 ±4.19 11.93 ±0.68 N/A
Table 4: Patient characteristics and serum biochemical parameters of peripheral blood sample groups.
*Data represents mean values for each group ± SEM. AAC: abstinent alcoholic cirrhosis; PBC: primary biliary






























1 45 F 28.6 0.11 12.09 0.49 0.05 D Y 7
2 46 M 49.4 0.3 10.65 1.25 0.38 A N 2
3 53 M 39.5 0.56 5.11 1.8 1.01 A N 7
4 45 M 12.3 0.23 6.28 1.21 0.28 A N 5
5 40 F 19.8 0.12 7.23 2.15 0.26 A N 3
6 73 M 101.7 0.01 9.62 0.61 0.01 D Y 3
7 32 M 81.5 0.04 18.97 0.82 0.03 D Y 7
8 45 F 32.9 0.05 7.52 2.2 0.11 A N 4
9 40 M 33.25 0.16 14.55 0.68 0.11 A Y 6
10 43 F 49.9 0.18 26.97 1.55 0.28 A Y 7
11 47 F 64.36 0.10 5.8 0.73 0.07 A Y 7
12 66 F 36.8 0.08 5.74 1.32 0.11 A N 1
13 55 F 15 0.02 8.85 1.75 0.04 A N 2
14 68 M 39.6 0.04 4.61 0.97 0.04 A Y 6
15 37 M 183 0.93 6.72 0.71 0.66 A Y 4
Table 5: Data profile for patients with alcoholic hepatitis.
Total CD34+ numbers are adjusted from the total mononuclear cell counts (lymphocytes) multiplied by CD34+count




CFU CD347CD45+ CFU CD347CD454
Mean SEM SD No. Mean SEM SD No.
Normal 44.75 28.42 56.85 4 1 0.71 1.41 4
Alcoholic hepatitis 153.75* 38.36 76.73 4 41* 23.69 47.37 4
Table 6: Total CFU frequency ofCD347CD45+ cells and CD34/CD45* cells were increased in the AH groups as
compared with the NC groups.




















Quad Events % Gated % Total
UL 640397 98.82 64.04
UR 5760 0.89 0.58
LL 1907 0.29 0.19
LR 4 0.00 0.00









Figure 19: Circulating CD34+ cell enumeration using flow cytometry.
A) Forward scatter vs side scatter dotplot with a selected gate around the low side scatter population of
mononuclear cells (Rl) which predominantly comprise of lymphocytes. B) The selected mononuclear cell
population is then displayed on a CD45 vs CD34 dotplot and the cluster of CD34VCD45 intermediate events
detected are gated (R2). The CD347CD45 intermediate population selected (R2) is quantified as a percentage
of the total events gated in the first stage of analysis i.e. low side scatter mononuclear cells.
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Figure 20











n=12 n=21 n=15 n=7
Normal Chronic injury AH Paracetamol injury
Figure 20: Peripheral blood CD34" count is significantly increased in patients with AH compared to NC
and other forms of acute or chronic liver in jury.
Values are expressed as a percentage of mononuclear cells present in the serum sample. Data represents mean















Figure 21: Peripheral blood CD34+ CFU counts are significantly elevated in AH patients compared to
normal controls.
Values are expressed as CFU's counted per plate. Data represents mean values for each group ± SEM. *p<0.05






Figure 22: Images ofCFUs obtained from CD347CD45+ stem cell culture assays.
A)MultilineageCFU-GEMM (granulocyte, erythrocyte, macrophage andmegakaryocyte). B-C) Large erythroid
colony BFU (burst-forming unit). D) Granulopoietic colonies of CFU-GM (granulocytes and macrophages).
Original magnification: A-D, 60x.
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Figure 23
CXCR4 expression on CD34+ cells
Normal Chronic liver injury AH Paracetamol
■ CXCR4% r iCXCR4-GM
Figure 23: No significant difference in CXCR4 expression on peripheral blood CD34+ cells in all liver
injury groups.
Values are expressed as a percentage of CD34+ cells expressing CXCR4 and Geometric Mean (GM) of
CXCR4. Data represents mean values for each group ± SEM.
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Figure 24
CXCR3 expression on CD34+ cells
Normal Chronic liver injury AH Paracetamol
Figure 24: No significant difference in CXCR3 expression on peripheral blood CD34+ cells in all liver
injury groups.
Values are expressed as a percentage of CD34+ cells expressing CXCR3 and Geometric Mean (GM) of
CXCR3. Data represents mean values for each group ± SEM.
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CHAPTER 5
Inflammatory cytokines and chemokines
regulating hepatic recruitment of HSCs
in human alcohol induced liver injury
108
5.1 Introduction
Murine and human studies have shown that the chemokine SDF-1 plays an important
role in the mobilisation of HSCs from the BM, both in the absence and presence of
liver injury and is involved in recruiting HSCs into injured livers and induces the
proliferation of endogenous HOCs (Kollet et al. 2003; Lapidot & Petit 2002; Petit et
al. 2002; Terada et al. 2003). Other cytokines such as MMP-9, G-CSF, IL-8, NE, MIG,
IP-10, RANTES and MCP-1 have also been implicated in the mobilisation and hepatic
migration of HSCs although their role in the mobilisation and recruitment of HSC in
clinical liver injury has not been defined. In this chapter (Chapter 5) we aim to study
the role of these inflammatory cytokines and chemokine axes in the mobilisation and
recruitment of HSCs in alcohol induced liver injury.
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5.2 Patient and methods
5.2.1 Patient details and sample collection for serum chemokine analysis
The patient cohort that was studied for the mobilisation of HSCs in peripheral
blood (Chapter 4) were also used for the serum chemokine analysis study. Serum
was collected from peripheral blood samples of healthy volunteer controls and from
patients attending the Royal Infirmary of Edinburgh from October 2002 to June 2004.
Ethical approval for the study was granted by the Lothian Health Board Research
and Ethics Committee (LREC/2000/4/187) and patients gave informed consent to use
the blood samples for experimental purposes. Patients with AH, chronic abstinent
alcoholic cirrhosis, primary biliary cirrhosis (PBC), untreated hepatitis C virus (HCV)
and acute paracetamol injury were included in this study. Blood samples from AH
patients were taken within the first week of admission and for acute paracetamol injury
patients taken within 76 hours of admission. All other patient blood samples were
taken at routine out patient clinic visits.
Blood samples were obtained from 8 normal healthy volunteers (2 Female, 6 Male,
Mean age 28yrs), 11 AH patients (6 Female, 5 Male, Mean age 49yrs), 5 acute
paracetamol injury patients (1 Female, 4 Male, Mean age 36yrs), and 20 chronic
liver injury patients comprising of: 9 chronic abstinent alcoholic cirrhosis patients (1
Female, 8 Male, Mean age 48yrs), 5 untreated HCV patients (2 Female, 3 Male, Mean
age 43yrs) and 6 PBC patients (all Female, Mean age 58yrs). Patient characteristics
and biochemical parameters for all sample groups are summarised in table 7.
Blood samples fromAH patientswere included ifthey fulfilled the fol lowing parameters:
1) Recent alcohol abuse (>400gm/week), 2) Jaundice (serum bilirubin >50pmol/l), 3)
one or more of the following criteria: hepatomegaly, pyrexia, leukocytosis and 4) No
previous documented history of alcoholic cirrhosis. We did however accept that in this
AH patient group there would be a proportion of patients with established alcoholic
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cirrhosis on admission even though it may have not been previously documented or
identified. Exclusion criteria were concurrent sepsis, corticosteroid treatment, recent
gastrointestinal bleeding and significant co-morbidity such as cardiorespiratory failure
or neoplasia. Seven out of the eleven patients with AH (64%) included in this study
were treated with Pentoxifylline which has been shown to decrease TNF-a gene
transcription as well as the production of other cytokines and chemokines including IL-
1(3, IL-6, IFN-y, IL-8, NE, MCP-1 and RANTES (Gutierrez-Reyes et al. 2006;Morgan
& McClain 2000a; Neuner et al. 1994;Oka et al. 1991;Seldon et al. 1995). All 7 AH
patients treated with Pentoxifylline had significant AH with a Maddrey's DF >32. We
acknowledge this as a limitation of the study and will address these limitations further
in the discussion Chapter 6. Currently there no published evidence to suggest that
Pentoxifylline has any effect on SDF-1, MMP-9, G-CSF, MIG or IP-10 levels.
Peripheral blood samples (lOmls) were collected into unheparinised beaded tubes and
allowed to clot for 30 minutes followed by 10 minutes centrifugation at 3000g. The
serum layer was separated by pipette into 0.5ml eppendorf tube aliquots and stored in
the dark at -20°C. Samples were thawed to 4°C prior to analysis and used once only
to avoid repeated freeze-thaw cycles of the serum samples.
5.2.2 Serum SDF-1, MMP-9, G-CSF and neutrophil elastase analysis
Serum levels of SDF-1, MMP-9, G-CSF and neutrophil elastase (NE) were measured
by enzyme linked immunosorbent assay (ELISA) using the Quantikine® immunoassay
kit for human SDF-1 a, MMP-9 (total), G-CSF (R&D Systems Europe Ltd, Oxon, UK,
DSA00, DMP900, DCS50) and the InnoZyme™ assay kit for human neutrophil elastase
(Calbiochem, California, USA, CBA 016). These assays use a quantitative sandwich
immunoassay technique. lOOpL of assay diluent was added to each well followed
by lOOpL of standard or sample. The microplate was incubated for 2 hours at room
temperature on a horizontal orbital microplate shaker set at 500 ± 50 rpm. Each well
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was washed 4 times with a wash buffer. 200pL of either SDF-1, MMP-9 or G-CSF
conjugate was added to each well and the microplate was again incubated for 2 hours
at room temperature on the shaker. Washing was repeated and 200pL of substrate
solution was added to each well whilst protected from the light. After incubation at
room temperature for 30 minutes, stop solution was added to each well and the optical
density measured using a microplate reader (Dynatech Laboratories, Chantilly, USA,
MR5000). All determinations were performed in duplicate. Concentrations of SDF-
1, MMP-9, G-CSF and NE were calculated by generating a standard curve, using
the optical density obtained to determine the corresponding concentrations. Serum
SDF-1 and G-CSF concentrations were expressed as pg/mL and MMP-9 and NE
concentrations as ng/mL. The minimum detectable concentration levels for SDF-1, G-
CSF, MMP-9 and NE was 18pg/mL, 0.4pg/mL, 0.156ng/mL and 0.063ng/mL.
5.2.3 Serum IL-8, IP-10, MIG, RANTES and MCP-1 chemokine analysis
Serum levels of IL-8, IP-10, MIG, RANTES and MCP-1 were quantified with the
BD™ Cytometric Bead Array (CBA) kit (BD Biosciences, Cowley, UK, 552990),
which uses a series of particles with discrete fluorescent intensities to simultaneously
detect multiple soluble analytes. The BD CBA Capture Bead mixture is in suspension
to allow for the detection ofmultiple analytes in a small volume sample. Three bead
populations with distinct fluorescent intensities have been coated with monoclonal
capture antibodies specific for IL-8, IP-10, MIG, RANTES and MCP-1.
For each sample, 25pil capture beads were mixed with 25pl PE-conjugated detection
antibodies, and then incubated with 50pl of either recombinant chemokine standards
or patient serum for 3 hours in the dark. Samples were washed in lmL dilution media
and then centrifuged at 200 x g for 5 minutes. Supernatant from each assay tube was
aspirated and discarded and the bead pellet was resuspended with 300pl of dilution
media. The samples were analysed in the FL3 channel of a FACS CALIBER®5 flow
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cytometer and approximately 1800 events were gated in total. Sample results were
generated in graphical and tabular formats using the BD™ CBA Analysis Software.
Serum IL-8, IP-10, MIG, RANTES and MCP-1 concentration values were expressed
as pg/mL. The minimum detectable concentration levels for IL-8, IP-10, MIG,
RANTES and MCP-1 were 0.2pg/mL, 2.8pg/mL, 2.5pg/mL, 1.0 pg/mL and 2.7pg/mL
respectively.
5.2.4 Patient details for SDF-1, MMP-9 and NE Immunohistochemistry
Archival liver biopsy tissue was used from 5 adult normal controls (NC) and compared
with 4 patients who had a history of continuous alcohol consumption >400gms/week,
no clinical or serological evidence of other causes of liver disease and had histological
evidence of alcoholic hepatitis (API) on biopsy. The following histological criteria
were used for the diagnosis ofAH in this study: 1) Macrovesicular and microvesicular
steatosis, 2) polymorphonuclear cellular infiltrate, 3) intracellular accumulation of
Mallory's hyaline/bodies and 4) evidence of hepatocellular injury or necrosis.
Ethical approval for the use of archival liver biopsy tissue in this study was granted by
the Lothian Health Board Research and Ethics Committee (2003/R/GI/02). Sample
sizes for the control and AH patient groups was limited in this study due to the
restrictions placed by the ethical approval committee. Patient and clinical details for
3 out of the 5 control specimens labelled as normal were not available. These 3 NC
samples labelled were re-examined by a pathologist (Prof DJ Harrison) and verified
histologically that they appeared normal. The remaining 2 NC samples were from
pre transplant female donor livers aged 47 and 62 years respectively, both died of
subarachnoid haemorrhage and had no clinical history of pre-existing liver disease.
Both tissue samples were documented as normal on histopathology reporting. The 4
AH liver biopsies specimens were from 1 female aged 52 and 3 male patients aged 38,
48, and 31 years respectively. Histopathological diagnosis of all liver samples were
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based on the original pathological report and re-examined by a pathologist (Prof DJ
Harrison).
5.2.5 Immunohistochemistry and cell counting for SDF-1, MMP-9 and NE
Immunohistochemical staining was performed on 3-micron-thick, formalin fixed
paraffin embedded tissue sections using selected antibodies. After deparaffination
and hydration, slides were microwaved on high power for 20 minutes in 2.1gm/L
Citrate (pH6) solution and then blocked in 1% H202 for 15 minutes. Sections were
incubated with a single selected primary antibody: Neutrophil elastase mouse mAb
(DakoCytomation, M0752) 1:100 dilution at room temperature, SDF-1 rabbit anti-
human mAb (Pasteur Institute, Paris, France, K15C) 1:50 dilution at 4°C overnight and
MMP-9 goat anti-human mAb (Biogenesis, Poole, UK, 5980-0911) 1:100 dilution at
4°C overnight. The NE and SDF-1 labelled slides were washed and then incubated for
40 minutes at room temperature with an HRP polymer-conjugated detection antibody
(DakoCytomation EnVision™ + System-HRP, K4006/K4010). The MMP-9 labelled
slides were washed and incubated for 30 minutes in a 1:400 dilution of biotinylated
rabbit anti-goat immunoglobulins (DakoCytomation, E0466) followed by wash and a
further 30 minutes incubation with an Avidin-Biotin Horseradish Peroxidase reagent
(Vectastain Elite ABC kit, PK6100). All slides were then washed and incubated
with DAB substrate chromagen (DakoCytomation) and counterstained with Mayer's
haematoxylin.
For SDF-1 staining, each section was screened on low power (200x) under a light
microscope (Olympus B061, Japan) and then a minimum of 5 portal tracts from each
biopsy specimen was photographed at a magnification of 320x using a colour digital
camera (Pixera Penguin Pro 150ES, USA). Two separate assessors who were blinded
to the nature of the biopsies viewed all sections from the digital images taken at 320x
magnification and determined the SDF-1 staining intensity per sample. The intensity
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of SDF-1 staining was graded semi-quantitatively from 0-3+ and a median score was
taken for the NC and AH group. The scale was defined as follows: 0= negative, 1+ =
weakly positive, 2+ = moderately positive, 3+ = strongly positive.
To evaluate the amount of positive nuclei staining for MMP-9 and NE, each section
was visualised under a light microscope (Olympus B061, Japan) and 10 random fields
per liver biopsy were selected and photographed at 320x magnification using a colour
digital camera (Pixera Penguin Pro 150ES, USA). Two separate assessors who were
blinded to the nature of the biopsies viewed all sections from the digital images taken
at 320x magnification and counted the amount of positive staining nuclei per field.
5.2.6 Statistics
All statistical analysis was performed on SPSS® 12.0 for Windows® software (SPSS
Inc. Chicago, IL). Results are expressed as the Mean with Standard Error of the Mean
(SEM) for individual group data. Differences between groups in the serum chemokine
study were analysed with a one way analysis of variance (ANOVA) test with post-
hoc Dunnets test to compare each group with NC. For the immunohistochemistry
studies the Mann-Whitney U statistical test (non-parametric significance) was used to
determine whether the differences between the AH and NC groups were significant.
Results were considered significant when p<0.05. The Cohen's kappa coefficient was




5.3.1 Serum SDF-1, MMP-9 and G-CSF levels are significantly elevated in
patients with alcoholic hepatitis
Patients with AH had significantly increased serum SDF-1 and MMP-9 levels (1440
± 300 pg/mL, p<0.05; 322.9 ± 86.40 ng/mL, p<0.05) as compared with the NC group
(393 ± 92 pg/mL, 85.29 ± 26.47 ng/mL). There was no significant increase in serum
SDF-1 or MMP-9 levels in either the acute paracetamol (977 ± 135 pg/mL, p>0.05;
69.94 ± 10.82 ng/mL, p>0.10) or chronic liver injury groups (1071 ± 112 pg/mL,
p>0.05; 133.88 ng/mL, p>0.10) when compared with the NC group (see figure 25 -
26). Serum G-CSF levels in the AH group was significantly increased (34.23 ± 10.19
pg/mL, p<0.01) as compared with the NC group (1.03 ± 1.03 pg/mL). There was no
significant increase in serum G-CSF levels in either the acute paracetamol (6.13 ±
5.79 pg/mL, p>0.05) or chronic liver injury groups (6.29 ± 1.96 pg/mL, p>0.05) as
compared with NC (see figure 27).
The serum NE levels were significantly elevated in only the AH group (1.81 ± 0.45 ng/
mL, p<0.05) when compared to NC (0.33 ±0.12 ng/mL) (seefigure 28) but this rise in
NE did not correlate with the corresponding serum MMP-9 rise (r2= 0.0427) nor with
the circulating CD34+ levels (r2= 0.1883) in AH patients. This observed rise in NE
levels is most likely due to activation of peripheral blood neutrophils asAH liver injury
is a neutrophil driven process and is characterised by a peripheral blood neutrophilia.
Our AH patient group also demonstrated a significant rise in circulating neutrophil
count (10.6 ± 2.07 x 109/1, p<0.05) as compared with the NC (3.32 ± 0.46 x 109/1).
There was no significant difference in serum NE levels in either the acute paracetamol
(0.10 ± 0.02 ng/mL, p>0.10) or chronic liver injury groups (0.83 ± 0.25ng/mL, p>0.05)
as compared with NC. Likewise, there was no significant increase in neutrophil counts
in either the acute paracetamol (4.41 ± 0.72 x 109/l) or chronic liver injury group (4.81
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± 0.78 x 109/1) suggesting there was not significant neutrophil activation in these forms
of liver injury.
5.3.2 Serum IL-8, IP-10, MIG, RANTES and MCP-1 levels demonstrate a
non specific response to liver injury
Serum IL-8 levels were significantly raised in all types of liver injury (AH: 149.14 ±
44.18 pg/mL, p<0.001; acute paracetamol: 113.06 ± 88.50 pg/mL, p<0.01; chronic
injury: 33.23 ± 7.54 pg/mL, p<0.01) when compared withNC (3.93 ± 0.65pg/mL) (see
figure 29). Furthermore there was no correlation between IL-8 levels and MMP-9 or
CD34+ levels. Serum IP-10 and MIG levels were significantly raised in the AH (570.42
± 224.59 pg/mL, p<0.05 and 915.02 ± 485.48 pg/mL, p<0.05), acute paracetamol
(757.06 ± 432.88 pg/mL, p<0.05 and 1796.5 ± 835.73 pg/mL, p<0.01) and chronic
liver injury groups (516.37 ± 131.67 pg/mL, p<0.05 and 805.95 ± 201.59 pg/mL,
p<0.05) when compared with NC (82.78 ± 15.41 pg/mL, p<0.05 and 116.23 ± 26.23
pg/mL) (seefigure 30-31).
Serum RANTES levels were decreased in all the liver injury groups when compared to
theNC (3593.27 ±267.14 pg/mL, p<0.05), although this reduction was only statistically
significant in the paracetamol (1611.98 ± 413.32 pg/mL, p<0.05) and chronic liver
injury groups (1679.59 ± 182.70 pg/mL, p<0.05) and not to the AH group (2378.70 ±
586.97 pg/mL, p>0.05) (see figure 32). Serum MCP-1 levels were only significantly
raised in the paracetamol injury group (441.18 ± 206.84 pg/mL, p<0.05) and not in
the AH group (112.09 ± 13.74 pg/mL, p>0.10) or chronic liver injury group (127.24 ±
24.27 pg/mL, p>0.10) when compared to NC (77.69 ± 15.83 pg/mL) (seefigure 33).
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5.3.3 SDF-1 expression is reduced and MMP-9/NE expression unaltered in
the livers of patients with alcoholic hepatitis
Examination of the liver tissue sections demonstrated positive SDF-1 staining on
biliary epithelial cells in both the NC and AH group specimens. There was no staining
for SDF-1 in the hepatocytes, inflammatory cells, vascular epithelial cells or other
liver parenchymal cell components in either theAH or NC sections. Overall there was
less intense SDF-1 staining of the biliary epithelium in the AH sections as compared
with the NC group (median staining intensity 1+ vs. 2+ (range 1-3). (seefigures 34-35
and table 8). The Cohen's kappa coefficient for the inter-observer agreement on SDF-
1 staining intensity was 0.7714.
In both the NC and AH sections MMP-9 staining was noted predominately in
neutrophils within the hepatic parenchyma as well as in activated Kupffer cells of the
hepatic sinusoids. No MMP-9 staining was observed within hepatocytes or biliary
epithelium in either the NC orAH group. Staining for MMP-9 in all liver sections was
uniform and did not vary in intensity. There was no apparent difference in the amount
ofMMP-9 positive staining cells between the AH and NC groups (7.37 ±1.17 cells
perfieldvs. 7.32± 1.43 cells per field, p>0.10) (seefigures 36-37). The Cohen's kappa
coefficient for the inter-observer agreement on MMP-9 cell counting was 0.6909.
Positive NE staining was identified in neutrophils within the hepatic parenchyma as
well as in the hepatic sinusoids in both the NC and AH sections. No NE staining was
observed within hepatocytes or biliary epithelium in either group. In all liver sections
staining for NE was uniform and did not vary in intensity. There was no difference in
the amount ofNE positive staining cells between the AH and NC groups (9.05 ±3.14
cells per field vs. 8.45 ±1.71 cells per field, p>0.10) (seefigures 38-39). The Cohen's
kappa coefficient for the inter-observer agreement on NE cell counting was 0.6701.
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5.4 Conclusion
We demonstrated thatAH patients (whose circulating CD34+ counts are elevated) have
significantly increased serum SDF-1, MMP-9 and G-CSF levels as compared to con¬
trols in non time course blood samples. We failed to demonstrate a similar increase
in SDF-1, MMP-9 and G-CSF levels in other forms of acute and chronic liver injury
studied. Serum NE, IL-8, IP-10, MIG, RANTES and MCP-1 levels demonstrated
non specific responses to alcohol induced liver injury. Patients with severe AH were
treated with Pentoxifylline which may have had an influence on the chemokine profile
results. Hepatic expression of SDF-1 was reduced in AH whilst MMP-9 and NE ex¬














Mean Age in years 49.2 ±3.8 36.5 ±4.2 50 ±2.1 28.3 ±3.1
Male: Female Ratio 5:6 4:1 11:9 6:2








313.4 ±78 128 ±27 46.9 ± 12 25 ± 5.9
Serum ALT concentration
(IU/1)*
54.9 ± 11.8 4337 ±421 50.1 ± 8.1 28 ±5.3
Serum albumin concentration
(g/1)*
29.1 ± 1 28.4 ± 1.2 37 ± 1.8 47 ± 2.1
Prothromin Time
(seconds)*
25.8 ± 10.5 36.8 ±5.8 11.93 ±0.68 N/A
Table 7: Patient characteristics and biochemical parameters of serum chemokine sample groups.
*Data represents mean values for each group ± SEM. AAC: abstinent alcoholic cirrhosis; PBC: primary biliary
cirrhosis; HCV: hepatitis C virus; ALT: alanine-amino transferase; N/A: not available.
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Table 8
Liver biopsy Median SDF-1 staining intensity (range)
Normal (n=5) 2+(1-3)
AH (n=5) 1+ (1-3)
Table 8: Staining intensity of SDF-1 reduced in AH liver sections when compared to NC.
















Normal Chronic injury AH Paracetamol injury
Figure 25: Serum SDF-1 levels are significantly increased in AH patients compared to NC.
Individual and mean values are represented for each group. MDC: Minimal detectable concentration. *p<0.05














Normal Chronic injury AH Paracetamol injury
Figure 26: Serum MMP-9 levels are significantly increased in AH patients compared to NC.
Individual and mean values are represented for each group. MDC: Minimal detectable concentration.*p<0.05
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Normal Chronic injury AH Paracetamol injury
Figure 27: Serum G-CSF levels are significantly increased in AH patients compared to NC.
Individual and mean values are represented for each group. MDC: Minimal detectable concentration. **p<0.01













Normal Chronic injury AH Paracetamol injury
Figure 28: Serum NE levels are significantly increased in AH patients compared to NC.
Individual and mean values are represented for each group. MDC: Minimal detectable concentration. *p<0.05
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Normal Chronic injury AH Paracetamol injury
Figure 29: Serum IL-8 levels are significantly increased in all liver injury groups compared to NC.
Individual and mean values are represented for each group. MDC: Minimal detectable concentration. **p<0.01
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Normal Chronic injury AH Paracetamol injury
Figure 30: Serum IP-10 levels are significantly increased in all liver in jury groups compared to NC.
Individual and mean values are represented for each group. MDC: Minimal detectable concentration. *p<0.05

















Normal Chronic injury AH Paracetamol injury
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Figure 31: Serum MIC levels are significantly increased in all liver injury groups compared to NC.
Individual and mean values are represented for each group. MDC: Minimal detectable concentration. *p<0.05



















Normal Chronic injury AH Paracetamol injury
Figure 32: Serum RANTES levels are not significantly altered in AH patients compared to NC.
Individual and mean values are represented for each group. MDC: Minimal detectable concentration. *p<0.05
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Normal Chronic injury AH Paracetamol injury
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Figure 33: Serum MCP-1 levels are not significantly altered in AH patients compared to NC.
Individual and mean values are represented for each group. MDC: Minimal detectable concentration. *p<0.05
compared to normal control.
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Figure 34
Figure 34: Immunohistochemical staining for SDF-1 in normal liver sections.
A-D) Liver biopsy sections from normal controls stained for SDF-1 (brown). Intense SDF-1 staining is only
expressed in the biliary epithelium (arrows). Original magnification: A,100x; B-C, 200x; D, 320x.
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Figure 35: Immunohistochemical staining for SDF-1 in AH liver sections.
A-D) Liver biopsy sections from patients with AH stained for SDF-1 (brown). Less intense SDF-1 staining is
visualised in the biliary epithelium (arrows). Original magnification: A, 200x; B-D, 320x.
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Figure 36
Figure 36: Immunohistochcmical staining for MMP-9 in AH liver sections.
A-D) Liver biopsy sections from patients with AH stained for MMP-9 (brown). MMP-9 staining was noted in
neutrophils within the hepatic parenchyma as well as in activated Kupffer cells (arrows). Original magnification:
A-D, 320x. Images C & D have been magnified to demonstrate neutrophil MMP-9 staining.
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Figure 37
Figure 37: Immunohistochemical staining for MMP-9 in normal liver sections.
A-D) Liver biopsy sections from normal controls stained for MMP-9 (brown). MMP-9 staining was noted
predominately in neutrophils within the hepatic parenchyma as well as in activated Kupffer cells of the hepatic
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Figure 38: lmmunohistochemical staining for neutrophil elastase (NE) in AH liver sections.
A-D) Liver biopsy sections from patients with AH stained for NE (brown). NE staining was noted in neutrophils
within the hepatic parenchyma (arrows). Original magnification: A-B, 200x; C, 320x; D, 600x.
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Figure 39: Immunohistochemical staining for neutrophil clastasc (NE) in normal liver sections.
A-D) Liver biopsy sections from normal controls stained forNE (brown). NE staining was noted in neutrophils





In this thesis we attempt to address an important area of research in both basic and
clinical hepatology: The role of BM-derived stem/progenitor cells in liver fibrosis
and regeneration. We aimed to study this in clinical patients and focus on a subset of
patients with alcohol related liver injury in which the contribution of the bone marrow
has not been extensively studied. The studies presented in this thesis were designed to
answer the following specific questions:
1. Does mobilisation and hepatic recruitment of HSCs occur in alcohol induced
liver injury and if such mobilisation contributed to a reparative process?
2. Do mobilised HSC in alcohol induced liver injury display true stem cell
potential properties?
3. Do inflammatory cytokines and chemokine axes regulate the mobilisation and
hepatic recruitment ofHSCs in alcohol induced liver injury?
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6.1 Mobilisation of circulating HSCs in alcohol induced liver
injury
We have demonstrated that CD34+ HSCs levels from non time course blood samples
were elevated in patients with acute alcoholic hepatitis, suggesting that there was
mobilisation of CD34+ cells into the circulation. We failed to demonstrate a similar
significant elevation in circulating CD34+ counts in other acute or chronic liver injury
groups studied, suggesting that this mobilisation of CD34+ HSCs may be specific for
AH and not a general response to liver injury. The observed elevated CD34+ numbers
could have arisen through a failure of CD34+ cells to engraft, both back into the bone
marrow or into the liver and thus create a slow increase in the number of circulating
CD34+ cells. However, it is likely that outside of the bone marrow niche environment,
HSCs would be unable to remain undifferentiated. HSC's differentiate into myeloid,
lymphoid and mesenchymal stem cells and give rise to populations of macrophages,
lymphocytes and myofibroblasts. Most of these cells would retain CD34+ expression,
but lose it shortly after lineage specific differentiation. Hence, circulation of CD34+
cells is likely to be short lived, and a slow build up of these cells would be unlikely.
We recognise that a single blood sample specimen provides only one snapshot
interpretation and may not be the most appropriate time point temporally. Mobilisation
of CD34+ cells during liver injury may also occur in waves, and our results may be
influenced by the timing of our samples in relation to the kinetics of the process. This
issue could be addressed by collecting serial blood samples on sequential days from
patients (Days 1,3,5,7, 10, and 14) and analysing the CD34+cell count for the different
time points. Samples would be taken not only from the AH patients but also from the
normal controls, acute paracetamol injury patients and chronic liver injury patients
to demonstrate any temporal variation in CD34+ levels and to help us understand the
kinetics of CD34+ mobilisation in AH and other forms of liver injury.
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The patient sample groups included in the peripheral blood CD34+ study were selected
to be representative of a broad range of acute and chronic liver injury as well as being
sufficiently common to have clinical relevance and provide adequate numbers. In
the AH group we aimed not to include patients with previous documented alcoholic
cirrhosis, although this patient group is heterogeneous and there would be a proportion
of patients with established alcoholic cirrhosis included even though it may not have
been previously documented or identified. The chronic liver disease patients were
all clinically stable and this group could be further optimised to include patients
with more severe forms of these chronic diseases such as decompensated PBC and
decompensated HCV cirrhosis. Inclusion of such groups could further clarify whether
CD34+ mobilisation was specific for AH or a more generalised response to severe
forms of liver injury.
AH patients were screened to ensure that sepsis, bleeding, severe co-morbidities and
prednisolone use would not be confounding factors that may have had an effect on the
bone marrow and influence our results. However patients treated with Pentoxifylline
for severe AH were included in this study as this was standard medical therapy for
patients with severe AH and by excluding these patients from our study it would
limit our sample size and be less representative of the spectrum of severity of AH
patients. Pentoxifylline is not known to directly inhibit HSC mobilisation although it
does modify the host immune responses and has an effect on cytokine expression such
as 1L-8, MCP-1 and RANTES that may have an effect on stem cell physiology. We
recognise that Pentoxifylline could influence our results and one possible method of
addressing this issue is by taking serial blood samples for CD34+ cell counts from AH
patients both pre and post Pentoxifylline treatment to see any temporal or quantitative
effect it may have. These results could be compared with a time course evaluation of
peripheral blood CD34+ cell counts from AH patients not treated with Pentoxifylline
and used as a reference point to demonstrate any variation in CD34+ levels.
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HSC mobilisation in AH has not been previously reported and studies on the extent of
peripheral blood HSC mobilisation in acute or chronic liver injury is limited. A study
by De Silvestro et al has demonstrated elevated peripheral blood HSC levels following
extensive liver resection in patients with malignant, primary or secondary liver diseases
(De Silvestro et al. 2004). The authors however did not investigate whether there were
increased CD34+ cell populations within the surgically operated liver and this raises
the question of whether the phenomenon seen, was due to a non specific systemic
response to surgical trauma or not. A more recent study by Lemoli et al demonstrated
HSCs mobilisation to be more pronounced in liver transplant patients with ischaemic/
reperfusion injuries early after surgery (day 3+) as compared with patients undergoing
liver resections suggesting that the greater the extent of liver tissue injury the higher
the degree of HSC mobilisation (Lemoli et al. 2006).
In contrast, Di Campli et al failed to demonstrate a time course CD34+ cell mobilisation
in hepatectomy patients or in patients with acute decompensation of liver cirrhosis (Di
Campli et al. 2005) and concluded that under these circumstances the liver can rely on
mature hepatocytes or endogenous progenitor cells to regenerate and repair itself. Our
data would support their conclusions because we failed to demonstrate mobilisation
of CD34+ cells in patients with acute paracetamol liver injury or established liver
cirrhosis although these were not serial time course blood samples from these groups.
It is possible that in these forms of liver injury, other modes of hepatic regeneration
were sufficient and thus the contribution ofHSCs from the peripheral circulation is not
required (Sell 2001). It is possible that in specific forms of liver injury such as alcohol
induced injury, where there is a specific inhibition of hepatocyte proliferation is there
mobilisation and recruitment of circulating HSCs into the liver as a response to liver
injury.
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6.2 Stem cell potential of mobilised HSCs
The results from our colony forming assays demonstrate that the CD34+ HSCs found
in blood were functional and had stem cell properties, in that they could form colonies
when incubated in the methylcellulose growth media. In addition, different types of
colonies were produced from the assays proving that such cells were pluripotent. We
were interested to find that there was an increased number ofCFUs formed from sorted
CD347CD45+ cells ofAH patients as compared with NC group. This would indicate
that mobilised HSCs from AH patients were not only as potent as NC but may also
display a true stem cell potential at a level higher than that seen with HSCs from healthy
controls. Although we did not perform CFU assays on circulating CD347CD45+
cells from acute paracetamol and other chronic liver injury patients, this could be
undertaken in future studies and serve as a further control group to compare the effects
of different types of liver injury on stem cell potential. The CFU assay has allowed us
to demonstrate haematopoietic stem cell properties, although more relevant would be
the ability to look at the potential of sorted CD34+/CD45+ cells to form hepatic cells
or fibroblasts. Studies in vitro have been successful in differentiating bone marrow
stem cells into hepatocyte marker expressing cells using bone marrow haematopoietic
cells cultured with hepatocytes or with stem cell growth factor, hepatocyte growth
factor, epidermal growth factor and fibroblast growth factor-4 (Okumoto et al.2003;
Lemoli et al.2006). Fiver specific gene and protein markers such as alpha feto protein,
cytokeratin 8, cytokeratin 18, cytokeratin 19 and albumin can be detected with reverse
transcription polymerase chain reaction (RT-PCR) and immunocytochemical analysis.
Likewise, bone marrow cells have been successfully cultured in vitro to produce
fibroblast colony forming cells and expression of fibrocyte markers such as pro(al)I
collagen, fibronectin, and vimentin mRNA can be detected with RT-PCR (Castro-
Malaspina et al. 1980;Ebihara et al. 2006).
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Although we did not investigate for hepatic or fibroblast differentiation potential in
mobilised CD34+/CD45+ cells in our study, these methods could be adapted for use
in future studies to evaluate whether these circulating cells have increased hepatic or
fibroblast differentiation potential.
Our observation that CD34VCD45+ cells were also producing higher total CPU counts
in the API group as compared with NC would suggest that other non CD34" progenitor
cells (with pluripotent stem cell properties) such as MSC, multipotent adult progenitor
cells (MAPC), CD 1337 CD34 endothelial progenitor cells and side population (SP)
cells may also be released into the peripheral circulation in alcohol induced liver injury
and would merit further study.
6.3 HSCs hepatic recruitment and contribution to liver fibrosis
6.3.1 Bone marrow derived CD347CD31" cells and hepatic progenitor cells
The liver biopsies from cross-sex liver transplant patients with acute alcohol injury
demonstrated increased Y+ recipient CD347CD31 cells whilst the liver biopsies from
non transplant AH patients contained a greater number ofCD347CD31 and c-kit7mast
cell stem cells when compared with controls. The co-localisation of Y-chromosome
and CD347CD3T markers in the alcohol injured cross-sex liver biopsies would
suggest that these cells were of bone marrow haematopoietic stem cell origin although
it has been documented that fibrocytes in human peripheral blood can also express
the haematopoietic cell marker CD34+ and the leukocyte marker CD45+ (Bucala et al.
1994). Other markers for HSCs such as c-Kit+, Thy+, Lin+, Sca-1+ and IL-7R+ have
been described and these markers could be used in FISH studies to better characterise
the bone marrow lineage of Y+ recipient CD347CD31~ cells. We have demonstrated
that non transplant AH liver biopsies contained a greater number of CD347CD31 and
c-Kit7mast cell hepatic progenitor cells stem cells. There are however other markers
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for hepatic stem cells such as epithelial cell adhesion molecule (EpCAM), neural cell
adhesion molecule (NCAM) and cytokeratin 19 and these markers could be used in
future work to further characterise the hepatic stem cells content in alcohol induced
liver injury biopsies (Zhang et al. 2008).
We acknowledge that the numbers ofpatients studied to assess the contribution ofbone
marrow stem cells to hepatic parenchyma, myofibroblasts and progenitor populations
was small and a greater numbers of patients would further bolster the validity of these
observations. This could be achieved by obtaining ethical approval to extend access
to archival liver transplant biopsies tissue taken at the Royal Infirmary of Edinburgh
from 1993 up to present day, as well as accessing cross sex transplant biopsies tissue
from other transplant units. The cross sex liver biopsy specimens from alcohol injury
patients provide only one snapshot interpretation of a dynamic process and the timing
of the biopsies was highly variable (13-63 months). By obtaining greater number
of alcohol injured cross-sex transplant biopsy specimens we could analyse whether
duration of bone marrow stem cell engraftment and contribution to the myofibroblast/
parenchymal population is altered over time. Furthermore an additional control
group could be included to look at cross sex transplant biopsies from patients with no
significant evidence of liver injury but at similar time points to those of the alcohol
injury group. The normal control group in the hepatic progenitor study was sub-
optimal in that clinical data was not available for some samples. The limited control
sample size could however be expanded to include more pre transplant donor biopsies
in which clinical and biochemical data would be available including liver biopsies
from living related liver donors.
6.3.2 Bone marrow derived myofibroblasts
We were interested to observe that there was little contribution of BM derived stem
cells to hepatocyte or biliary cell lineages. Instead, we observed that BM derived
recipient (Y+) cells contributed to the myofibroblast population (a-SMA+) within
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the alcohol injured liver of transplant patients. We did not specifically address the
mechanisms by which Y7 a-SMA+ cells contributed to the myofibroblast population
and this could have occurred either via spontaneous cell fusion of recipient cells with
activated hepatic stellate cells or myofibroblasts in the transplanted liver, or BM
recipient cells acquiring a myofibroblast phenotype through trans-differentiation. One
possible way of addressing the above scenario would be co-staining for Y-chromosome
and X-chromosome using FISH in the cross-sex liver transplant biopsies. In the case
of fusion we would expect to see XXXY cells, but in the case of trans-differentiation
we would expect to see XY or XYXY cells. Considering the rodent study by Kisseleva
et al which demonstrated that BM derived cells contributed via transdifferentiation to
collagen producing fibrocytes then it would seem more probable that a similar process
of myofibroblast transdifferentiation would occur in transplant patients with alcohol
induced liver injury (Kisseleva et al. 2006). We did not further characterise the Y7 a-
SMA+ myofibroblast cells for other fibrocyte markers such as vimentin or fibulin-2 nor
test for functionality of the Y7 a-SMA+ cells although further proof of their fibrogenic
potential could be evaluated using a method described by Forbes et al whereby active
collagen transcription in myofibroblasts is demonstrated by in situ hybridisation for
pro (al) I collagen expression (Forbes et al. 2006).
6.3.3 CD34+ hepatic myofibroblasts
A proportion of the myofibroblasts co-stained for CD34 suggesting that a population of
CD34+ cells within the liver was contributing to the hepatic myofibroblast population.
We have been unable to categorally demonstrate whether these CD347a-SMA+ cell
populations were of bonemarrow haematopoietic stem cell origin or not due to technical
difficulties of simultaneous staining for CD34, CD31, a-SMA and Y-chromosome on
the same tissue section. One possible method of addressing this challenge is to use
serial 3 micron thick sections and stain neighbouring sections for CD34/ CD31/Y and
CD34/a-SMA/Y respectively as this procedure would allow for matching fields to be
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as close as possible to each other. We did however demonstrate that a number of true
progenitor cells (CD347CD31 ) and a-SMA+ cells were Y+ chromosome, as well as a
number of these CD34+ cells co-expressing a-SMA+ thus proving that all combinations
of these three cell markers were present. In our study the number of Y7a-SMA+ cells
was higher than the number ofCD347a-SMA+ cells suggesting that other BM derived
cell populations such as mesenchymal stem cells or fibrocytes were also possibly
contributing to the myofibroblasts population. A rodent model of carbon tetrachloride/
Thioacetamide induced liver cirrhosis, has demonstrated that BM stem cells contribute
significantly to hepatic stellate cell and myofibroblast populations and originate from
both mesenchymal and HSC populations (Russo et al. 2006). Furthermore our results
are compatible with Abe et al who describes a circulating population of fibrocytes
in human peripheral blood that in vitro could be induced to express a-SMA+ and it
has been documented that fibrocytes express haematopoietic markers CD347CD45+,
myeloid markers and collagen (Abe et al. 2001;Bucala et al. 1994). From this study
we have shown that BM derived stem cells can become myofibroblasts or CD34+
expressing cells in the alcohol injured liver. Furthermore, it is also possible that a
population of CD34+ cells within the liver was contributing to the recipient derived
myofibroblast population in alcohol liver injury (see figure 40). The exact origins of
these CD347a-SMA+ cells is uncertain although the possibility exists that they could
be derived from circuilating mesenchymal or HSC stem cells or alternatively from an
endogenous hepatic source.
6.3.4 Hepatic parenchymal cell proliferation
BM stem cells are known to play a role in stimulating endogenous hepatocyte
proliferation in a paracrine fashion as evidenced by their contribution in rodent and
human studies (Yannaki et al. 2005; Gaia et al. 2006). However we failed to demonstrate
any increased proliferation of hepatic parenchymal cells in the cross-sex liver grafts
with alcohol liver injury, suggesting that this was not a significant mechanism by
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which endogenously mobilised stem cells promote liver repair in alcohol liver injury.
It is possible that BM stem cell stimulation of endogenous hepatocyte proliferation
occurs in other forms of liver injury that was not examined in this study. Furthermore
it is possible that myofibroblasts and other mesenchymal-type cells in alcohol induced
liver injury may generate morphogens or growth factors that facilitate liver repair via
alternative mechanisms other than hepatocyte proliferation however this possibility
was not examined in the current study.
6.4 Inflammatory cytokines and chemokines regulating
mobilisation and hepatic recruitment of HSCs
6.4.1 SDF-1/CXCR4
We demonstrated that AH patients with raised circulating CD34+ levels have
significantly increased serum SDF-1 levels as compared to controls in non time course
blood samples. Currently there is no published evidence to suggest that Pentoxifylline
has any effect on SDF-1 levels although such an influence could be addressed by taking
serial blood samples fromAH patients both pre and post Pentoxifylline treatment to see
any temporal or quantitative effect it may have on serum SDF-1 levels. Furthermore,
these results could be compared with a time course evaluation of serum SDF-1 levels
from AH patients not treated with Pentoxifylline. Several studies have demonstrated
increased circulating plasma levels of SDF-1 in autoimmune and viral diseases, in
conjunction with increased expression of SDF-1 in the parenchyma of rejecting
liver transplants and viral/autoimmune liver diseases (Goddard et al. 2001; Terada
et al. 2003) suggesting that liver injury may by the expression of SDF-1, produce a
concentration gradient, which in turn facilitates the recruitment of inflammatory cells
and HSCs from the BM into the circulation. We failed to demonstrate an increase in
circulating serum levels of SDF-1 in the paracetamol and chronic liver injury groups
although these were non time course blood samples and our results may be influenced
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by the timing of our samples in relation to the kinetics of the process. Murine studies
from our laboratory have demonstrated that both circulating CD34+ and serum SDF-
1 levels are elevated in cocaine induced periportal liver injury with an associated
increase in the plasma to BM ratio of SDF-1. This would suggest that reversal of the
BM/peripheral blood SDF-1 gradient with an increase in plasma SDF-1 is associated
with stem cell mobilisation (Gilchrist et al. 2007). The chemokine assay has allowed
us to demonstrate elevated SDF-1 concentrations in serum of AH patients, although
future studies would need to measure bone marrow SDF-1 levels to determine if an
SDF-1 gradient is established between the BM and peripheral circulation which in
turn facilitates HSCs mobilisation in alcohol induced liver injury. Hepatic SDF-1
expression has been reported in a variety of conditions such as liver allograft rejection
(Goddard et al. 2001), viral and autoimmune liver diseases (Kollet et al. 2003; Terada et
al. 2003). It is however unclear if this expression is an attempt to recruit inflammatory
cells or HSCs towards the damaged organ, or if it is indeed entirely unrelated. In
our study SDF-1 immunohistochemical staining was reduced in the AH liver biopsy
sections when compared to the normal controls and SDF-1 expression was confined
to the biliary epithelium. Only rodent studies with HOC regeneration models have
demonstrated increased hepatic SDF-1 protein up-regulation (Hatch et al. 2002),
whilst non-oval cell regeneration liver injury models did not produce SDF-1 protein.
We would have expected SDF-1 expression to be increased in the liver parenchyma of
AH patients however this was not the case. Possible explanations for this observation
are: 1) Our sample size for both groups were small and the normal control group
contained pre transplant donor biopsies and specimens with no clinical history which
may not have been the most appropriate and could have affected our results, 2) The
liver biopsy specimens provided only one snapshot interpretation and may not be the
most appropriate time point temporally and 3) The possibility that AH liver injury
inhibits both hepatocyte and endogenous hepatic progenitor cell regeneration resulting
in reduced hepatic SDF-1 protein expression.
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The AH, NC, paracetamol and chronic liver injury groups all had similar HSC
CXCR4 receptor profiles suggesting that chemokine receptor expression was not
significantly altered in the mobilisation process of CD34+ stem cells in liver injury.
The functionality of the CXCR4 receptors was however not tested and it is possible
that CXCR4 receptor function on circulating CD34+ cells could have been altered
despite any changes seen in receptor expression. CXCR4 receptor function could be
assessed in future experiments employing methods such as Transwell chemotaxis
assays to SDF-1 concentration gradients as described by Kollet (Kollet et al. 2003) or
measuring changes in intracellular calcium in circulating CD34+ cells in response to
SDF-1 sensitisation.
6.4.2 MMP-9
Serum MMP-9 levels were elevated in non time course blood samples fromAH patients
(whose circulating CD34+counts were raised) whilst they were not significantly
elevated in the serum of either the acute paracetamol or chronic liver injury groups.
This suggests that MMP-9 expression in alcohol induced liver injury was a specific
response and a previous study by Watanabe et al has demonstrated that in mice with
anti-Fas antibody (Jo2) induced acute hepatitis, MMP-9 expression in the circulation
was elevated and accompanied by the recruitment of HSCs from the BM into the
circulation (Watanabe, Haruyama, & Akaike 2003). It is possible that the observed
rise in serum MMP-9 levels in AH patients influences HSC mobilisation however
MMP-9 is also known to play various important roles in tissue inflammation, and
organ remodelling (Birkedal-Hansen et al. 1993;Visse & Nagase 2003) all of which
may offer an alternative explanation for this observed rise. Previous studies have
demonstrated elevated serum and plasma MMP-9 levels in various types of acute and
chronic liver injuries although this observation may reflect the role MMP-9 has on
tissue inflammation, tumour growth and organ remodelling. It is however also possible
that the timing of blood samples the severity of the liver injury groups studied and the
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use of Pentoxifylline treatment in some AH patients may have influenced the results
too. Currently there is no published evidence to suggest that Pentoxifylline has any
effect on MMP-9 levels although such an influence could be addressed by taking
serial blood samples from AH patients both pre and post Pentoxifylline treatment and
compared with a time course evaluation of serum MMP-9 levels from AH patients
not treated with Pentoxifylline to see any temporal or quantitative effect.There was
no apparent difference in the intensity or amount of MMP-9 staining in liver tissue
between the AH and NC groups, suggesting that MMP-9 may be produced by other
cell types such as circuilating neutrophils, endothelial cells or connective tissue cells
rather than parenchymal cells in the liver and be responsible for the elevated serum
MMP-9 levels observed in AH patients.
6.4.3 G-CSF
Serum G-CSF levels were elevated inAH patients whose circulating CD34+ cell counts
were significantly increased, suggesting that G-CSF may have an effect on mobilising
circulating CD34+. Furthermore, Lemoli at al has demonstrated that in OLT patients
with ischaemic reperfusion injury a significant increase in circulating CD34+ cells was
associated with elevated serum G-CSF levels (Lemoli et al. 2006). We did not detect
elevated levels of serum G-CSF or CD34+ levels in either the acute paracetamol or
chronic liver injury groups suggesting that G-CSF enhanced mobilisation of CD34+
cells was a specific response to alcohol induced liver injury as compared to acute
paracetamol injury and the other forms of chronic liver injuries studies. Factors such as
timing of samples, degree of severity of the other forms of liver injury studied and the
effect Pentoxifylline may have on G-CSF levels would need to taken into consideration
although currently there is no published evidence to suggest that Pentoxifylline has
any effect on G-CSF levels.
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Murine liver injury studies have suggested that G-CSF promotes endogenous repair
and proliferation of host hepatocytes in the injured liver. We did not have liver biopsies
available from the AH patient group with elevated G-CSF and CD34+ levels to test
this hypothesis directly although indirectly we observed that the cross-sex liver grafts
with alcohol induced liver injury did not demonstrate an increase in the proliferation of
hepatic parenchymal cells. It may be possible that G-CSF promotes myofibroblasts and
other mesenchymal-type cells in alcohol induced liver injury to generate morphogens
or other growth factors that facilitate liver repair however this possibility was not
examined in our current study. A recent human clinical study in which G-CSF was
administered to AH patients to induce HSC mobilisation did however demonstrate an
in increases hepatocyte growth factor and a proliferation of hepatic progenitor cells
in liver biopsies (Spahr et al. 2008). Whether these changes translated to a clinical
improvement was not assessed and perhaps larger human clinical trials may clarify
whether G-CSF can clinically and biochemically facilitate liver repair.
6.4.4 Chemokines IL-8, MIG, IP-10, RANTES, MCP-1 and NE
Serum IL-8, IP-10 and MIG levels were significantly raised in all types of liver injury
and may reflect a non specific inflammatory chemokine response to different types
of liver injury. These chemokines play important roles in recruiting inflammatory
cells including T-lymphocytes and neutrophils, and it is likely that the high levels
are involved in the recruitment of inflammatory cell infiltrate rather than specifically
CD34 cells. The chemokines MIG and IP-10 mediate their effect through chemokine
receptor CXCR3 and the chemokine receptors expression profiles on HSCs were not
significantly altered in all the liver injury groups and NC groups studied. As with
CXCR4, we did not specifically study for CXCR3 receptor function. Serum RANTES
and MCP-1 levels also demonstrated non specific responses to liver injury. Although
serum NE levels were significantly elevated in AH patients, this increase did not
correlate with serum MMP-9 or CD34+ levels suggesting that it was a marker for
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increased neutrophil activity only rather than demonstrating a role in regulating CD34'
stem cells. Factors such as timing of samples, degree of severity of the liver injury
models studied and the effect Pentoxifylline may have on these chemokine levels
make it difficult to draw any firm conclusions on the influence these mediators may
have in HSC physiology and alcohol liver injury. Liver injury is a complex process,
with a complex biochemical soup of mediators released at any one time, many of
which have overlapping effects (Simpson et al, 2003). In order to understand the true
effects a chemokine may be having, it is necessary to look at the whole picture and
assess functional gradients. That is, to measure the levels in the bone marrow, temporal
and quantitative measurements in serum as well as to obtain quantitative and special
characterisation of its levels within the liver.
6.5 Future studies
The data presented in this thesis has been extracted from three different cohorts of
patients and in the human setting it is difficult to ascertain if HSCs are modified or
primed in alcohol liver injury to contribute to liver repair or fibrosis. Murine studies
would be better placed to answer some of these key questions and attention could
then be directed as to why such cells do not result in adequate liver repair in clinical
practice. HSCs may well contribute to the reparative response, but the degree of stem
cell mobilisation may be inadequate, necessitating agents such as G-CSF. Furthermore,
endogenous stem cells may also be damaged in the alcohol liver injury process so
autologous sources of stem cells may be required for liver repair. In non-transplant
patients the presence of stem cell-derived parenchymal cells or fibroblasts cannot be
determined making assessment of stem cell contribution difficult. Stem cells (CD34+)
from alcohol liver injury and other types of acute and chronic liver injury patients
could be infused into pre-irradiated NOD-SCID mice and compared with similar cells
obtained from non-liver injury patients receiving G-CSF. Similarly CD34+ cells from
alcohol liver injury and non-liver injury patients receiving G-CSF could be infused into
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pre-irradiated NOD-SCID mice with ethanol induced toxicity. Immunohistological
analysis of murine livers could then be performed using human specific markers for
hepatocyte, biliary epithelium, myofibroblast, stem cells and endothelial cells markers.
Further evidence of human haematopoietic and hepatic parenchymal/myofibroblast
differentiation could be determined with established techniques of immunofluorescence
and fluorescent in situ hybridisation (FISH) for mouse and human DNA.Data has
shown that pre-treatment of circulating human CD34+ cells with anti-CXCR4 antibody
enhances their migration and repopulating potential into the bone marrow of NOD-
SCID mice (Plett et al. 2002).Investigate whether pre-treating stem cells (from alcohol
liver injury and GSCF stimulated non-liver injury patents) with anti-CXCR4 prior
to infusion will enhance their migration and hepatocytic differentiation in the NOD-
SCID mice livers would be of clinical relevance as it could demonstrate a potential
method ofmanipulating and priming stem cells for liver repair.
Human clinical trials have utilised G-CSF mobilised hematopoietic stem cells to study
the short term effects on liver regeneration and liver function. Future human clinical
randomised controlled trials in AH patients treated with G-CSF could assess the long-
term effects on clinical outcome and liver regeneration. Furthermore such studies
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could utilise bone marrow, serum and liver tissue samples to assess the changes in the
concentration of SDF-1, MMP-9, TNF-a, IL-8 and HGF in response to G-CSF and
correlate these changes with the degree of mobilisation and liver regeneration.
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6.6 Conclusion
In conclusion we have made the observation that human BM derived haematopoietic
stem cells are mobilised into the peripheral circulation and recruited into the liver
during alcohol induced liver injury. Whilst there was an expansion of HSCs and
hepatic progenitor cells within the liver there was no evidence of increased hepatocyte
proliferation. We demonstrated that in alcohol induced liver injury there is a marked
increase in the proportion of Y+ hepatic myofibroblasts suggesting that BM derived
recipient cells were contributing to the liver myofibroblast population. Furthermore, a
proportion of the myofibroblasts co-stained for CD34 suggesting that a population of
CD34+ cells within the liver were contributing to the hepatic myofibroblast population.
Serum SDF-1, MMP-9 and G-CSF levels were elevated in AH and could play a role in
regulating the mobilisation of CD34+ stem cells in alcohol induced liver injury.
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Figure 40
Figure 40: BM derived stem cells contribute to CD34+ and a-SMA+ liver population in alcohol liver
injury.
BM derived stem cells can become myofibroblasts or CD34+ expressing cells in the alcohol injured liver.
Hepatic CD34+ cells also contribute to the hepatic myofibroblast population.
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Epilogue
Current evidence suggests that HSC contribution to hepatocyte lineages is limited
and that BM stem cells may contribute to fibrogenesis within the liver. We have
demonstrated that HSC as a subset of the BM stem cell compartment have the ability
to contribute to pro-fibrotic cells in response to alcohol induced liver injury. It is
possible that BM stem cells may support liver repair through other mechanisms such
as production of growth factors, fibrosis resolution or even neoangiogenesis although
this is yet to be fully established. A more comprehensive understanding is needed
of the effect HSCs may have on the diseased liver and there is a theoretical concern
that BM stem cell therapy may promote fibrogenesis in cirrhotic livers or even have
the potential for malignant transformation. Future studies would need to establish a
better understanding of the factors regulating HSC homing, subsequent engraftment
into the liver and finally differentiation into various liver cell lines before the potential
therapeutic manipulation ofHSCs to treat liver disease is to be fully realised.
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abstract Bone marrow (BM) hematopoietic stem
cells (HSCs) have been shown to facilitate regeneration
in multiple nonhematopoietic tissues by either generat¬
ing epithelial cells or altering the inflammatory re¬
sponse. Depending on injury type, the predominant
mechanism of epithelial lineage regeneration occurs by
spontaneous cell fusion or transdifferentiation. Irre¬
spective of the mechanism, mobilization from the BM
is a prerequisite. Mechanisms by which HSCs mobilize
into damaged organs are currently under scrutiny.
Murine and human studies have shown that the chemo-
kine SDF-1 and its receptor CXCR4 participate in the
mobilization of HSCs from BM and in the migration of
HSCs to injured liver. SDF-1 is a potent HSC chemoat-
tractant and is produced by the liver. Production is
increased during liver injury leading to increased HSC
migration to the liver, a finding diminished by neutral¬
izing anti-CXCR4 antibodies. Additional factors have
been implicated in the control of hepatic migration of
HSCs such as IL-8, hepatocyte growth factor, and
MMP-9. Matriceal remodeling is an essential compo¬
nent in IISC engraftment, and MMP-9 expression is
increased in liver injury. This review focuses on the
complex interaction of chemokines, adhesion mole¬
cules, and extracellular matrix factors required for
successful migration and engraftment of HSCs into the
liver.—Dalakas, E., Newsome, P. N., Harrison, D. J.,
Plevris, J. N. Hematopoietic stem cell trafficking in
liver injury. FASEBJ. 19, 1225-1231 (2005)
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Bone marrow (BM) hematopoietic stem cells (HSCs)
have long been known to possess the unique capacity
for self-renewal and differentiation into hematopoietic
and mesenchymal cell lineages (1). That this plasticity
extended to nonhematopoietic lineages such as hepatic
oval cells, hepatocytes, cholangiocytes (1-3), skeletal
muscle cells (4), neurons (5), epithelial cells of the
lung, GI tract, and skin (6) is a relatively new observa¬
tion, and has raised hopes that such cells could in the
future be used for the regeneration and reconstitution
of damaged organ tissue. This process of epithelial
lineage regeneration appears to occur via a mechanism
of spontaneous cell fusion or transdifferentiation.
Emerging data in the field of cardiac regeneration
suggest that incoming stem cells can also contribute to
tissue repair by promoting neoangiogenesis and mini-
0892-6638/05/0019-1225 © FASEB
mizing cardiomyocyte apoptosis (7). Whatever the un¬
derlying mechanism by which the HSCs participate in
tissue regeneration, it will still require the presence of
HSCs to mobilize from the BM and reach their target
organ. The aim of this review is to summarize current
available information addressing the aspects of HSC
mobilization and trafficking in response to liver injury.
ADULT STEM CELLS AND
LIVER REGENERATION
While the liver is a mitotically quiescent organ in adult
humans and animals (8), hepatocytes have a remark¬
able capacity to meet the replacement demands during
cellular loss (9, 10). However, when either chronic/
extensive damage is inflicted on the liver or when
hepatocyte proliferation is inhibited, a facultative cel¬
lular compartment of hepatic oval cells (HOCs), lo¬
cated within the smallest branches of the intrahepatic
biliary tree is activated and leads to liver repair (10, 11).
More recently, several groups have demonstrated that
BM-derived HSCs may contribute to liver repair (1-3,
12-14). The contribution of HSCs to liver repair has
varied, but is generally related to the presence and
severity of liver injury. Thus, the restitutive response of
the liver to different injuries has been proposed to
include three levels of proliferating cells: 1) the hepa¬
tocyte, 2) the endogenous ductular progenitor cell or
HOC, and 3) a pluripotent stem cell derived from
circulating BM cells (9).
Controversy has recently arisen as to whether HSCs
contribute to the hepatocyte lineage in liver injury via
transdifferentiation alone or by adopting the pheno-
type of hepatocytes after spontaneous cell fusion (15).
Recent reports in favor of the fusion hypothesis have
demonstrated that adult cells can adopt the phenotype
of other cell lines by fusing with embryonal stem cells
(16, 17) as well as BM-derived hepatocytes generated by
in vivo cell fusion (18). In support of transdifferentia¬
tion, several groups have demonstrated that HSCs can
differentiate into hepatocytes (19, 20) and pancreatic
endocrine cells (21) without any evidence of cell fu¬
sion. The mechanism of HSC hepatic regeneration
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remains unresolved; clearly, any future stem cell re¬
search will have to distinguish HSC transdifferentiation
from fusion events. Whatever the mechanism of hepatic
regeneration is, the trafficking of HSCs to the liver may
play an important component of the reparative process
in liver injury.
The contribution of HSCs to hepatocyte lineages in
rodents and humans remains a controversial area with
data both supporting (1-3, 13, 14, 22) and rebutting
(23-25) findings. This may in part reflect the types of
cells used, the injury models used, and the methods
used to detect stem cell progeny. Nevertheless a thera¬
peutic role of HSCs in liver injury has been described in
rodents (13, 26), albeit with varying contributions of
transdifferentiation and fusion. In other models, par¬
ticularly in humans, the contribution that HSCs make
to liver repair by transdifferentiation is lower, on the
order of 0.011-20% (2, 3, 6, 27-29). To improve on this
level of contribution will require greater understanding
of the mechanisms by which stem cells mobilize from
the BM and home to injured organs. There remains a
pressing need for further studies to confirm or refute
the claims that stem cells can lead to improved liver
repair and hence survival in either a rodent or human
setting.
Murine and human studies have shown that the
chemokine stromal cell-derived factor-1 (SDF-1) and its
receptor, CXCR4, are involved in recruiting inflamma¬
tory cells into injured livers as well as inducing prolif¬
eration of endogenous HOCs (30, 31). SDF-1/CXCR4
interactions participate in the mobilization of HSCs
from BM and have been implicated in the migration of
human HSCs to the liver during injury (32, 33). Other
factors have been implicated in the regulation of he¬
patic migration of HSCs, including interleukin-8 (IL-8),
hepatocyte growth factor (HGF), and matrix metallo-
proteinases (MMPs).
ADULT STEM CELL MOBILIZATION AND
RECRUITMENT IN LIVER INJURY
Human studies have demonstrated increased levels of
circulating HSCs in response to a systemic injury such
as acute sickle cell crisis and surgical trauma (34, 35). A
recent study by De Silvestro et al. demonstrated that
peripheral blood HSC levels were elevated after exten¬
sive liver resection (36). Our group has demonstrated
that in patients with alcoholic hepatitis there is an
increase in circulating HSCs when compared with
normal controls (37). The extent to which these pe¬
ripheral blood HSCs are mobilized into the circulation
of patients with liver injury and contribute to liver
repair remains uncertain and is under investigation.
Release of HSC from the bone marrow
In the adult BM, the release of HSCs into the periph¬
eral circulation is regulated in part by the CXC chemo¬
kine SDF-1 and its receptor CXCR4 (32, 33, 38, 39).
SDF-1 is a potent chemoattractant for HSCs and is
produced by various BM stromal cell types and epithe¬
lial cells in a broad range of normal tissues, including
the liver (40-46) (see Table 1). It plays a major role in
the homing, migration, proliferation, differentiation,
and survival of many cell types including human and
murine hematopoietic stem/progenitor cells (32, 33,
38, 39, 47-50). Knockout mice deficient in SDF-1
exhibit disturbed hematopoiesis and knockout mice
deficient in the CXCR4 receptor die in utero (51, 52),
underlining their importance.
SDF-1 is highly conserved between mice and humans
(53, 54), mediating its effect through the CXCR4
receptor that is expressed on CD34+ HSCs, mononu¬
clear leukocytes, and a variety of stromal cells (53).
CXCR4 is a G-protein-coupled, 7-transmembrane re¬
ceptor and is the only known receptor for SDF-1 (55).
The interaction between SDF-1 and CXCR4 has been
demonstrated to trigger multiple intracellular signals,
including calcium mobilization and phosphorylation of
adhesion components such as extracellular signal-reg¬
ulated kinases 1 and 2 (ERK-1 and -2), proline-rich
tyrosine kinase 2 (Pyk-2), focal adhesion kinase (FAK),
and protein kinase C (PKC) (56, 57) In the adult BM,
release of HSCs into the peripheral circulation is
controlled in part by a concentration gradient of SDF-1
established within the BM microenvironment (39, 58,
59). Reduction of BM SDF-1 levels has been shown to
result in release of HSC into the peripheral circulation,
an effect mediated partly by granulocyte colony-
stimulating factor (G-CSF), which induces the release
and proliferation of neutrophil proteases such as
elastase, cathepsin G, and MMPs (33). Increased
expression of SDF-1 in the peripheral circulation
facilitates further mobilization of HSCs down a con¬
centration gradient (60).
Several reports demonstrate increased circulating
plasma levels of SDF-1 in autoimmune and viral dis¬
eases, in conjunction with increased expression of
SDF-1 in the parenchyma of rejecting liver transplants
and viral/autoimmune liver diseases (31, 61). These
observations have been reported in murine liver injury
models (12, 30), suggesting that liver injury may, by the
TABLE 1. SDF-1 expression in normal human tissue
Tissue type Cell line SDF-1 expression
Bone marrow Stromal cell lines
Tonsil Epithelial cells in tonsillar crypt
Spleen Reticular cells
Fetal liver Mesothelial cells, biliary epithelium, ductal
plate
Adult liver Biliary epithelium
Lung Interstitial cells
Cardiac Cardiac myocytes
Brain Glial cells, cortical neuronal cells,
astrocytes
Muscle Skeletal myocytes
Skin Epithelial cells of sweat glands, endothelial
cells, pericytes, dendritic cells
Thymus Stromal cells, medullary cells, epithelial
cells
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expression of SDF-1, produce a concentration gradient
between liver and BM, which in turn facilitates the
recruitment of inflammatory cells and HSCs from the
BM into the circulation and then into the liver (12, 31)
(see Fig. 1A-C).
The mechanism by which SDF-1 influences HSC
mobilization is unclear, although it is thought to in¬
volve specific changes to the adhesion of progenitor
cells to the BM microenvironment via the modulation
of adhesion molecules such as the integrin-dependent
very late antigen-4 (VLA-4) (62). In vitro there is an
increased trans-endothelial migration of human pro¬
genitor cells toward a gradient of SDF-1 (48, 63), and
SDF-1 has been shown to promote the survival of
circulating CD34+ HSCs by counteracting apoptosis via
the activation of the phosphotidyl inositol 3 kinase
(PI3-K)/Akt pathway (64).
It has been speculated that the release of proteolytic
enzymes and chemokines from injured liver into the
circulation could also facilitate mobilization and re¬
cruitment of HSCs (12). Studies with G-CSF have
revealed neutrophil proteolytic enzymes such as elas-
tase, cathepsin G, and MMPs, including MMP-2 and
MMP-9, result in the proteolytic degradation of SDF-1
in the BM, thus facilitating the release of stem cells (33,
65). MMPs degrade extracellular matrix proteins and
are known to play important roles in tissue inflamma¬
tion, tumor growth, and organ remodeling (66, 67).
MMPs are secreted as zymogens (pro-MMPs) that are
activated by a variety of proteinases and inhibited by
tissue inhibitors of metalloproteinases (TIMPs) and
oi2-macroglobulin (66). In humans, MMP-9 is produced
in a wide variety of cells types such as neutrophils,
progenitor cells, endothelial cells, fibroblasts, connec¬
tive tissue cells, tumor cells, and parenchymal cells,
including the liver (66, 68). Human and animal studies
have demonstrated that MMP-9 promotes the release of
progenitor cells from the BM into the circulation by 1)
inducing the release of soluble kit-ligand (sKitL) from
BM stromal cells, which accelerates the proliferation
and migration of HSCs, 2) clearing the interaction of
adhesion molecules VLA-4/vascular cell adhesion mol-
ecule-1 (VCAM-1) between stromal cells and HSCs in
the BM, and 3) enhancing the SDF-1 induced migration
potential of HSCs across the subendothelial basement
membrane (38, 69-71). In addition, MMP-9-induced
recruitment of HSCs may occur via other mechanisms
such as the shedding of membrane-bound stem cell
factor (SCF) and the secretion of MMP-9 by progenitor
cells in response to SDF-1 stimulation (70, 71). MMP-9
has been demonstrated to have an active involvement
in liver remodeling in cirrhosis and inflammation as
well as regulating hepatocyte regeneration after partial
hepatectomy (72-74).
Human studies have demonstrated elevated serum
and plasma MMP-9 levels in various types of liver injury
including acute allograft rejection (75), ischemic reper-
fusion injury (76, 77), chronic viral hepatitis (78, 79),
and alcoholic liver cirrhosis (80), suggesting there is a
correlation between disease severity/progression and
MMP-9 expression. In these studies, 70-80% of the
serum and plasma MMP-9 measured, appeared in the
active complex form and could be detected in serum
samples from as early as 30 min and >1 wk after an
acute injury process. In chronic liver diseases such as
alcoholic cirrhosis, persistently elevated plasma activi¬
ties of MMP-9 have been demonstrated, suggesting its
expression reflects a process of ongoing extracellular
matrix remodeling (80). Carbon tetrachloride (CC14)
-induced liver injury studies in rats and NOD/SCID
mice (in which bone marrow cells were seen to trans-
differentiate into hepatocytes) demonstrated an in¬
creased expression and activation ofMMP-9 in the liver,







Figure 1. A) Release of HSCs
from bone marrow into periph¬
eral circulation mediated via
SDF-1 concentration gradient.
B) Release of HSCs into periph¬
eral circulation enhanced via
MMP-9 and IL-8. C) Recruit¬
ment of HSCs into injured liver





in the stress-induced recruitment of HSCs from the BM
to the injured liver (12, 81). A recent study by Hanu-
megowda et al. (82) has demonstrated an increased
activation of MMP-9 in the livers of rats with monocro-
taline-induced liver injury (which inhibits hepatocyte
proliferation and promotes an HOC response). This
increase in MMP-9 activity was produced from either
the endothelial cells or from an activation or influx of
inflammatory cells into the injured hepatic paren¬
chyma (82). In a study by Watanabe et al, mice were
injected with anti-Fas antibody (Jo2) to induce an
acute hepatitis, demonstrating that MMP-9 expres¬
sion in the circulation was elevated and accompanied
by the recruitment of HSCs from the BM into the
circulation (83).
Interactions between MMP-9 and other chemokines
such as IL-8 have been demonstrated in mobilization
studies whereby MMP-9 is rapidly induced in neutro¬
phils after exposure to IL-8 and resulting in the release
of HSCs into the peripheral circulation (84-87) (see
Fig. IB). Elevated IL-8 levels have been demonstrated
in the circulation and hepatic parenchyma of many
human liver conditions including alcoholic hepatitis,
viral hepatitis, chronic alcoholic liver disease, and acute
graft-vs.-host disease after liver transplantation (88-92).
Thus IL-8, a known neutrophil chemoattractant in liver
disease, also has the potential to induce the release of
HSCs into the peripheral circulation via an indirect
mechanism requiring the activation of circulating neu¬
trophils and the release of MMP-9 (86).
Hepatic recruitment of HSCs in liver injury (Fig. 1C)
Kollet et al. have recently demonstrated the key role
that SDF-l/CXCR4-mediated signaling plays in the
migration of human progenitors to the murine liver.
Neutralization of the CXCR4 receptor with an anti-
CXCR4 antibody significantly inhibited the homing of
human cord blood or mobilized peripheral blood
CD34+ stem cells to the liver of irradiated NOD/SCID
mice (12). Furthermore, injection of human SDF-1 into
the murine liver parenchyma further enhanced the
hepatic migration of human stem cells. SDF-1 expres¬
sion has been reported in a variety of liver and nonliver
conditions such as liver allograft rejection (61), viral
and autoimmune liver diseases (12, 31), ischemic brain
injury (93), myocardial infarction (94), inflammatory
skin conditions (44), and BM injury induced by total
body irradiation or chemotherapy (95). It is unclear
whether this expression is an attempt to recruit inflam¬
matory cells or HSCs toward the damaged organ or is
indeed entirely unrelated.
SDF-1 expression in rejecting liver transplants and
viral/autoimmune liver diseases was seen to be con¬
fined to the biliary epithelium and other nonparenchy-
mal cells, thus promoting the retention of CXCR4+
Ivmphocytes and possibly HSCs in the portal tracts (12,
31, 61). Hatch et al. (30) were able to demonstrate that
SDF-1 protein was up-regulated in the membrane frac¬
tion of the whole liver lysates. Notably, however, this
was only the case in animals that had undergone HOC
regeneration models [partial hepatectomy (PH) and
2-acetylaminofluorene (2-AAF) or 2-AAF and CC14],
Animals that had undergone non-oval cell regeneration
models of PH, CC14 alone, and 2-AAF alone did not
produce SDF-1 protein. Immunohistochemistry on the
oval cell regeneration model liver sections revealed
increased expression of SDF-1 in the hepatocytes adja¬
cent to the proliferating oval cells and positive CXCR4
staining on these oval cells. These data argue for the
defined production of SDF-1 in forms of liver injury
that may be attempting to recruit HSCs to the repara¬
tive process.
The cytokine HGF, which is produced in the non-
parenchymal perisinusoidal cells of the liver and in¬
duces hepatocyte proliferation, may also be involved in
the migration and differentiation of HSC into the
injured liver (12, 96). Increased expression of HGF has
been demonstrated in CC14-induced liver injury and in
rodent HOC regeneration models, suggesting it is
involved in stem cell proliferation, migration, and
differentiation (22, 97). Kollet et al. recently demon¬
strated that after liver injury, levels of HGF were
increased and contributed to the recruitment of hu¬
man CD34+ stem cells to the injured liver (12) by
increasing the motility of human progenitors and in
synergy with SCF potentiated both CXCR4- and SDF-1-
induced directional migration.
CONCLUSIONS
Many concepts regarding stem cell migration and plas¬
ticity come from studies of multipotent hematopoietic
stem cells and the molecular pathways of hematopoiesis
(98). There is now increasing evidence to suggest that
liver injury induces the expression and secretion of
signaling mediators such as SDF-1, IL-8, MMPs, HGF,
and SCF, which facilitate the homing and engraftment
of HSCs to the liver (12, 30, 31). Factors regulating
long-term engraftment and differentiation of HSCs
into hepatocytes are yet to be defined, although che¬
mokines, adhesion molecules, and extracellular matrix
factors would appear to have an important role to play.
A better understanding of the factors regulating HSC
homing, subsequent engraftment into the liver, and
finally differentiation into hepatocytes are essential if
the potential therapeutic manipulation of HSCs to treat
liver disease is to be realized. [tj]
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